**Table S 1. Distribution of *M. tb* complex strains, specimen source/s, genotyping method/s, molecular anti-TB drug resistance rate and resistance mechanisms in *M. tb* across African countries, January 2007 to December 2018**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  **Country****(**number of studies**)** | **Year** | Specimen Source/s | **Genotyping method/s** | **Strain//lineages/Sub-lineages** (number of isolate/s per study) | **Total isolates** (resistant isolate) | **Total isolates which DST is determined** | **Resistance****rate (%)** | **Antitubercular drug resistance mechanism/s (n)** | **Resistance mechanism diagnostic method/s used** | **Anti-TB drugs to which strains were mono-resistant (n)** | **MDR****(n)** | **XDR (n)** | **Ref/s** | **Reference** |
| **Algeria (1)** | 2015  | Sputum & Extrapulmonary samples | Spoligotyping  | LAM9 (27), LAM1 (2), H3-LAM9 (1), LAM6 (1), LAM4 (1), LAM3 (2), H3 (28), H2 (3), T1 (26), T2 (3), T3 (2), T2-T3 (1), X1 (1), S (7), H1 (7), USA (1H1) (1), U (likely-T3) (1), U (LAM3) (2), LAM 10-CAM (1) | 126 | - | - | *-* | - | - | - | - | (1) | (Ifticene et al., 2015) |
| **Angola (1)** | 2017 | Sputum  | Spoligotyping & MIRU-VNTR typing | LAM3 (4), LAM1/LAM9 (2), LAM2 (2), LAM6 (5), LAM1/LAM4 (1), LAM1 (16), T3/X3 (1), LAM9 (19), T1 (28), LAM8 (3), LAM4 (4), LAM10 (1), H3/T1 (1), T2 (1)  | 89  | - | - | *-* | - | - | - | - | (2) | (Perdigao et al., 2016) |
| **Benin (2)** | 2009  | Sputum  | Spoligotyping MIRU-VNTR | ST61 (40), ST1 (17), ST 438 (8) | 194 | - | - | - | - | - | - | - | (3) | (Affolabi et al., 2009) |
|  | 2017  | Sputum  | Spoligotyping  | Family-33 (2), Family-34 (1), Family- 36 (1), Beijing (8), CAS (1), LAM1 (1), LAM9 (1), LAM10 (46), T1 (17), T2(1), T4 (1), H1(1), H2 (1), H3 (4), *M. africanum* West-AFRI-1 (12), *M. africanum* West-AFRI-2 (1), *M. bovis* (1) | 100 | - | - | - | - | - | - | - | (4) | (Affolabi et al., 2017) |
| **Burkina Faso (2)** | 2009 | Sputum | *-* | - | 63 (36) | 63 | 57.1 | *rpoB*: D516V (14), H526D (5), H526Y (5), S531L (3), M515I+H526N (1), L533P (1), H526N (1); *kat*G: S315T (36); *inh*A-pro: T8C (7), T8A (5), C15T (2) | GenoType®MTBDR*plus* | INH[[1]](#footnote-1) (5), RIF[[2]](#footnote-2) (2) | 29 | - | (5) | (Miotto et al., 2009) |
|  | 2007 | Sputum  | Spoligotyping & MIRU-VNTR typing  | SIT772 (5), SIT61 (35), SIT57 (2), SIT53 (25), SIT47 (6), SIT516 (1), SIT78 (2), SIT848 (2), SIT504 (1), SIT523 (2), SIT100 (1), SIT50 (5), SIT592 (1), SIT589 (1), SIT203 (1), SIT26 (1), SIT200 (3), SIT187 (1), SIT342 (1), SIT62 (1), SIT494 (2), SIT60 (1), SIT655 (1)  | 120 | - | - | *-* | - | - | - | - | (6) | (Godreuil et al., 2007) |
| **Botswana (1)** | 2018 | Sputum  |  - | - | 260 (20) | 241 | 8.3 | *rpoB:* H526N (19),S531L(2); *katG*: S315T(13) | Single Molecule-Overlapping Reads (SMOR Assay) Technology  | *\**RIF(4), *\**INH(11) | 5 | - | (7) | (Shin et al., 2018) |
| **Cameroon (4)** | 2014 | Sputum | -  |  - | 163 (63) | 163 | 38.7 | *rpoB*: S531L (5), H526D (1), D516V (1), D516Y (1); k*atG*: S315T (18), S315N (1); *inh*A (*fab*G1*-inh*A regulatory region): C15T (3), G47C (5); *rpsL*: K43R (2); *gidB*: A138P (1), L79W (1), P75S (1), H48N (1), V36G (1); *embB*: M306V (1); *emb*A: L330L (3);  *emb*C: A20C (3), A230C (3) | ABI’s Big dye terminator kit (Applied Biosystems, USA) | ǂ*\**INH, ǂ*\**RIF, ǂ*\**STM[[3]](#footnote-3), ǂ*\**EMB[[4]](#footnote-4)  | 6 | - | (8) | (Tekwu et al., 2014) |
|  | 2013  | Sputum  | Spoligotyping  | Cameroon-family (260), T1 (55), T2 (48), Haarlem (103), LAM10-CAM (23), LAM9 (2), LAM1 (1), LAM2 (1), LAM5 (1), U (7), H3 (9), T5 (2), H1 (1), U (likely-H3) (2), AFRI-2 (8), AFRI-1 (3), AFRI-3 (2), CASI-DELHI (1) | 565  |  | - | *-*  | - | - | - | - | (9) | (Koro Koro et al., 2013) |
|  | 2016 | Sputum  | Spoligotyping & MIRU-VNTR typing | LAM1 (4), LAM10-CAM (278), T1 (42), T2 (27), H1 (20), H3 (20), U (16), U (likely-H) (13), AFRI-2 (8), AFRI-3 (4), BOV (1), BOVIS-1 (1), CAS1-DELHI (1), X1 (1) | 437 |  | - | *-* | - | - | - | - | (10) | (Koro Koro et al., 2016) |
|  | 2013 | Sputum  | Spoligotyping & MIRU-VNTR typing | LAM10-CAM (57), T1 (40), Uganda-I (10), U (likely-H3) (2), U (likely-H) (2), U (4), H1 (6), H3 (13), H37Rv (3), T5 (3), T2 (7), AFRI (1), AFRI-3 (1), LAM1 (2) | 169 |  | - | *-* | - | - | - | - | (11) | (Assam Assam et al., 2013) |
| **Chad (1)** | 2017 | Sputum  | Spoligotype & MIRU-VNTR. typing | AFRI-2 (2), Cameroon (130), CAS1 (18), EAI3-IND (2), H1 (61), H3 (17), LAM11-ZWE (1), MANU-1 (1), MANU-2 (2), S (2), T (3), T1 (24) T1-RUS2 (9), T2 (22), T3 (1), T5 (2), T5-RUS2 (5), X1 (3), X2 (7)  | 311(73) | 311 | 23.5 | *rpo*B: H526Y (5), H526D (4), S531L (15); *kat*G: S315T1(30); *inh*A-pro: C15T (19) | GenoType®MTBDR*plus* v.2  | RIF (17), INH (42) | 14 | - | (12) | (Ba Diallo et al., 2017) |
| **Congo (2)** | 2014 | Sputum | MIRU-VNTR typing  | Beijing strains (4), Cameroon-family (4), LAM-family (8), T-family (30) | 46 (21)\* | 46 | 45.7 | *rpo*B: D516V (9), S531L+V577M (1), D516Y (1), L511R+D516Y (1), L511P+D516Y (1), S531L (1), S531Q (1); *kat*G: S315T (13), H270P (1); *rps*L: K43R (4); *gyr*A: T80A+A90G (9); *gyr*B: G559A (1) | GenoType®MTBDR*plus* & GenoType®MTBDR*sl* | \*INH(4), \*RIF (0), \*STM (1), ǂMOX[[5]](#footnote-5), ǂOFL[[6]](#footnote-6),ǂAMK[[7]](#footnote-7) | 15\* | - | (13) | (Aubry et al., 2014) |
|  | 2017  | Sputum  | Whole genome sequencing, Spoligotyping, MIRU-VNTR typing |  CAS-DELHI (2), Beijing (1), EAI (1), West African-1 (6), LAM (12), Uganda-I (7), Uganda-II (1), Haarlem (4), X-type (3), Congo-type (26), Unclassified Euro-American Strains (11) | 74 (3)\* | 74 | 4.1 | *rpo*B*:* D516V (1), D516Y (1*); kat*G*:* S315T (3) | HiSeq & MiSeq systems (Illumina, San Diego, CA, USA) | ǂ\*INH, ǂ\*RIF, ǂ\*STM, ǂ\*PZA[[8]](#footnote-8), ǂ\*EMB | 2\*  | - | (14) | (Malm et al., 2017) |
| Ivory Coast **(3)** | 2015 | Sputum | - | - | 2(2)\* | 2 | 100.0 | *rpo*B: D516V (2); *kat*G: S315T (2); *gyr*A: D94G (2); *rrs*: A1401G (1); *eis*: C14T (1) | GenoType®MTBDR*plus* assay | \*RIF (0), \*INH (O), \*ETM[[9]](#footnote-9) (0), \*OFL (0), \*KAM [[10]](#footnote-10) (0),\*AMK (0), \*ETM (0) | 2\* | - | (15) | (N'Guessan et al., 2015) |
|  | 2016 | Sputum  | - | - | 63(60) | 63 | 95.2 | *rpo*B*:* D516V (23), H526D (6), H526Y (9), S531L (11), Ins 1542 TTC (1), D516Y (1), H526C (1), H526G (1), H526L (1), H526N (1), L533P (1), D516E & S522L (1), H526Q & L533P (1), A532A & L533P(1); *kat*G: S315T (60); *inh*A: T8A (11), T8C (16) | GeneXpert MTB/RIF assay & GenoType®MTBDR*plus* assay | ǂRIF, ǂNH | 55 | - | (16) | (N'Guessan Kouassi et al., 2016) |
|  | 2008 | Sputum  | - | - | 196 (24)\* | 196 | 12.2 | *kat*G*:* S315T (15); *rpo*B: H526Y (2), D516V (2), H526R(1), S533L (1), S531L (1); *mab*A*-inh*A *regulatory* C15T (3); *inh*A: C15T (2)  | ABI PRISM®310 DNA sequencer (Applied Biosystems, Foster City, CA) | ǂ\*RIF,\*INH (17) | 7\* | - | (17) | (N'Guessan et al., 2008) |
| **Djibouti (3)** | 2012  | Sputum  | Spoligotype & MIRU-VNTR typing  | AFRI-Variant (2), Beijing (1), BOV-Variant (1), CAS (1), CAS-Variant (3), CAS1-DELHI (5), CAS1-KILI (1), EAI (1), EAI-Variant (6), EAI1-SOM (1), EAI3-IND (3), EAI5 (3), EAI8-MDG (1), EAI8-MDGv (2), EAI-SOM (1), H1 (1), H2 (1), H3 (6), H3-Variant (1), H37Rv (1), LAM-Variant (5), LAM1 (1), LAM9 (1), S (1), S-Variant (1), T-Variant (2), T1 (5), T1-T2 (1), T2 (2), T3 (2), T3-ETH (2), T5-ETH-Variant (3), T4 (2), T4-CEU1 (1), U (2), U-Variant (3), X1 (3), X2 (1) | 435 |  | - | *-* | - | - | - | - | (18) | (Blouin et al., 2012) |
|  | 2010 | Sputum  | Spoligotyping & MIRU-VNTR typing  | CANET-II (1), EAI4-VNM (12), EAI8-MDG (1), EAI5 (1), T3-ETH (2), T1 (21), T2 (8), CAS1-DELHI (6), CAS1-KILI (8)  | 62  |  | - | *-* | - | - | - | - | (19) | (Godreuil et al., 2010) |
|  | 2016 | Sputum  | Spoligotyping & MIRU-VNTR typing  | X2 (1), LAM6 (1), T3-ETH (2), LAM7-TUR (3), T3 (1), LAM9 (2), CAS1-DELHI (3), CAS1-KILI (6), Beijing (1), EAI5 or EAI3 (3), EAI8-MDG (1), EAI11-SOM (1), Undefined (7) | 32 |  | - | *-* | - | - | - | - | (20) | Millan-Lou et al., 2016) |
| **Egypt (5)** | 2016 | Tuberculous lesions from (Cattle &, buffaloes) | - | - | 8 (2) | 8 | 25 | *inh*A (1)#; *rpo*B (1)# | GenoType®MTBDR*plus* assay V. 2.0 | RIF (1), INH (1) | - |  | (21) | (Abdel-Moein et al., 2016) |
|  | 2009 | Sputum | - | - | 155(76)\* | 155 | 49.0 | *rpo*B: D516V (4), S531L (13), H526C (2); *kat*G*:*  S315T (7), S315R (1); r*ps*L: K43R (4), K88R (6); *emb*B: M306I (2), M306V(2) | PCR-based single-strand conformationalpolymorphism (SSCP) analysis | \*RIF (3), \*INH (6), \*STM (21), \*EMB (2),\*PZA (2) | 25 | - | (22) | (Abbadi et al., 2009) |
|  | 2009 | Sputum  | - | - | 153 (50)\* | 153 | 32.7 | *rpo*B*:* D516V (4), S522L (1), H526D (6), S531L (9); *kat*G: S315T (24) | ABI Prism 310 Genetic Analyzer (Applied Biosystems, Foster city, Calif.,944041 USA). | \*RIF (6), \*INH (10), \*STM (4), \*EMB (4) | 13\* | - | (23) | (Abdelaal et al., 2009) |
|  | 2009 | Sputum  | Spoligotyping  | MANU2-var (5), T4-var (3), Beijing-var (1), CAS1-DELHI-var (4), CAS1-DELHI (2), S (2), T3 (1), T4 (3), LAM7-TUR (4), LAM9 (1), H3 (2), T1 (51), MANU-2 (33), T1-var (20), MANU ancestor (1), H3-var (1), T2-var (1), T3-var (2), LAM (1), LAM9-var (1), MANU-3 (1), MANU-ancestor-var Δ33(1) | 151 |  | - | *-* | - | - | - | - | (24) | (Helal et al., 2009) |
|  | 2016 | Sputum  | Spoligotyping,MIRU-VNTR, large sequencepolymorphism (LSPs) & Multi-locus sequence typing (MLST).  | CAS-DELHI (14), T1 (89), T2 (2), T3 (6), T4 (5), H1 (5), H3 (19), LAM (7), LAM1 (1), LAM3 (2), LAM5 (1), LAM6 (1), LAM7-TUR (8), LAM9 (9), LAM10-CAM (2), S (17) | 230  |  | - | *-* | - | - | - | - | (25) | (Diab et al., 2016) |
| **Ethiopia (36)** | 2017 | Sputum  | - | - | 89 (69) | 89 | 77.5 | *rpo*B: S531L (27), H526Y (2); *kat*G: S315T/L (31), *inh*A: C15T/A16G (1) | GenoType®MTBDR*plus* V 2.0 | ǂRIF, ǂNH  | 29 | - | (26) | (Meaza et al., 2017) |
|  | 2015 | Sputum & extrapulmonary samples | - | - | 413 (195) | 413 | 47.2 | *rpo*B*:* S531L (85), H526Y (19), H526D (7); *kat*G*:* S315T (155), Dele-315 (16), S315T2 (1); *inh*A*:* C15T (8*)* | GenoType®MTBR*plus* | INH (26), RIF (19) | 150 | - | (27) | (Mekonnen et al., 2015) |
|  | 2014 | Sputum | - | - | 736 (523) | 736 | 71.1 | *rpo*B: S531L (323), H526Y (31), H526D (19), D516V (13), H526D (19); *kat*G: S315T (456); *inh*A: C15T (5), S315T/-C15T (9), S315T/-A16G (1) | GenoType®MTBDR*plus* | ǂINH, RIF (42) | 427 |  | (28) | (Abate et al., 2014) |
|  | 2013 | lymph node aspirates  | - | - | 226 (13) | 226 | 5.8 | *kat*G: S315T (8); *rpo*B: S531L (2), Q513L (1); *emb*B: M306I (2) | GenoType®MTBR*plus* assay | INH (6), RIF (1), ǂEMB | 2 | - | (29) | (Biadglegne et al., 2013) |
|  | 2013 | Gastric lavage & sputum  | Spoligotyping | T3 (3), T1 (3), H4 (1), CAS1-DELHI (1), PST-01 (1), PST-02 (1), PST-03 (1), PST-04 (1), PST-05 (1), PST-06 (1), PST-07 (1) | 15 (1) | 15 | 6.7 | *inh*A (1)# | GenoType®MTBR*plus* assay | INH (1) | - | - | (30) | (Workalemahu et al., 2013) |
|  | 2012 | Sputum | - | - | 260 (45) | 260 | 17.3 | *kat*G: S315T (33); *inh*A: C15T (2); *rpo*B: S531L (11), H526D (1); *emb*B: M306I (2), M306V (1) | GenoType®MTBDR*plus* & GenoType®MTBDR*sl*   | ǂINH, ǂRIF, ǂEMB  | 13 | - | (31) | (Tessema et al., 2012) |
|  | 2016 | Sputum  | Spoligotyping & MIRU-VNTR typing  | Ethiopia-H37Rv like (30), Ethiopia-3 (18), CAS-DELHI (18), Euro-American Super lineage (17), LAM (4), Haarlem (8), Ural (6), Lineage 7 (3), EAI (2), X-type (2), Beijing (1) | 109 |  | - | *-* | - | - | - | - | (32) | (Ali et al., 2016) |
|  | 2015  | Sputum & fine needle aspirates  | Spoligotyping  | LAM1 (1), Ural-1 (6), T3 (3), Turkey (3), H3 (21), T (15), T2 (3), MANU-2 (6), LAM5 (1), X2 (2), T3-ETH (15), X1 (2), H1 (1), T4 (2), CAS1-DELHI (48), AFRI (14), BOV (1), BOV-1 (1), MANU-ancestor (1) EAI (3), T1-RUS2 (1), T-H37Rv (1), LAM3 (1), CAS (2), PINI2 (2), H2 (1), H (1), MANU1 (3) | 168 |  | - | *-* | - | - | - | - | (33) | (Nuru et al., 2015) |
|  | 2012 | Sputum  | Spoligotyping  | Beijing (1), CAS (42), H (24), LAM (3), T (95), Unknown (4), Orphans (23)  | 192 |  | - | *-* | - | - | - | - | (34) | (Mihret et al., 2012) |
|  | 2016  | Sputum | - | - | 279 (31) | 279 | 11.1 | *rpo*B*:* S531L (3), H526Y (2), *kat*G: S315T1 (22); *inh*A: C15T (2) | GenoType®MTBDR*plus* assay | RIF (6), INH (22) | 3 | - | (35) | (Bedewi Omer et al., 2016) |
|  | 2017  | Sputum  | Spoligotyping  | MANU-2 (31), T1 (43), T2 (7), T3-ETH (38), T3 (25), MANU-1 (11), H3-Ural-1 (6), T (25), CASI-DELHI (14), H3 (13), X2 (2), H1 (4), X1 (6), Turkey (7), LAM (2), AFRI (1), CASI-KILI (2), T1-RUS2 (2), LAM5 (1), EAI7-BGD-2 (2), H4-Ural-2 (1), MANU-3 (1) | 281 |  | - | *-* | - | - | - | - | (36) | (Bedewi et al., 2017) |
|  | 2015  | Sputum & lymph node asperities  | WGS (Illumina HiSeq) | Lineages: L4.1.2 (4), L4.2. ETH2 (2), L4.2. ETH1 (2), L4.10 (1), L4.6 (7), L3.1.1 (2), L3.4 (3), L3. ETH3 (2), L3. ETH2 (2), L3. ETH1 (5), L1.2.1 (5), L1.2.2 (3), L7 (25) | 1000 |  | - | *-* | - | - | - | - | (37) | (Comas et al., 2015) |
|  | 2014 | Sputum  | Spoligotyping | EAI8-MDG (1), LAM1 (3), CAS1-Delhi (14), S (1), T3 (12), LAM7-TUR (1), H3 (4), T2 (7), T1 (11), MANU-2 (14), MANU-1 (1), X1 (7), T3-ETH (10), MANU-ancestor (3), CAS (3), EAI2 (1), BOV (2), EAI6-BGD1 (2), EAI6-BGD1 (1), AFRI (1), T4 (1)  | 105 |  | - | *-* | - | - | - | - | (38) | (Belay et al., 2014) |
|  | 2009 | Biopsy, lymph node aspirates & blood specimens | Multiplex ligation-dependent probe amplification (MLPA) assay | Principal Genotypic Group-1 (PGG1) (2), PGG-2(48), PGG2- (Haarlem) (35), PGG-3(10) | 95 (11) | 95 | 11.6 | *kat*G: S315T (11) | MLPA assay  | INH (11) | - | - | (39) | (Beyene et al., 2009) |
|  | 2018 | Sputum  | Spoligotyping  | S (1), T3 (20), CAS (11), H3 (5), T1 (38), H1 (1), X1 (5), T2 (1), LAM9 (1), Indo-Oceanic-33 (1), IO-34 (1) | 86 |  | - | - | - | - | - | - | (40) | (Tilahun et al., 2018) |
|  | 2016 | Sputum  | - | - | 112 (44) | 112 | 39.3 | *rpo*B: S531L (28), H526D (1); *kat*G: S315T1 (36); *inh*A: C15T (4) | GenoType®MTBRplus (version 2.0)  | RIF (3), INH (10) | 31 | - | (41) | (Tadesse et al., 2016) |
|  | 2017 | Fine needle aspirates (FNA) | Spoligotyping & MIRU-VNTR typing  | BOVIS-1 (2), Beijing (1), CAS-DELHI (44), Haarlem (45), TUR (5), LAM (13), ETH-H37Rv-like (30), ETH-2 (44), Uganda-I (16), S (19), ETH-3 (34), Uganda-II (4), X (5), ETH-1 (Lineage7) (6), EAI (3), URAL (11) | 304 (10) | 279 | 3.6 | *rpo*B: (codon 447-452) (10) | GeneXpertMTB/RIF assay  | RIF (10) | - | - | (42) | (Tadesse et al., 2017) |
|  | 2015  | pleural, peritoneal & synovial fluids | Spoligotyping  | Beijing/W lineage (1), LAM3 (1), U (5), T3 (8), T1 (24), H3 (3), LAM9 (2), H1 (2), CAS (10), T4 (1), H4 (1), EAI4 (1) | 59 |  | - | *-* | - | - | - | - | (43) | (Korma et al., 2015) |
|  | 2016 | fine-needleaspiration (FNA) | Spoligotyping  | T3-ETH (14), T1 (19), T3 (6), T4 (1), CAS1-DELHI (7), CAS1-KILI (2), CAS (3), Family-33 (7), Family-36 (1), M.*bovis* (1), H1 (1), H3 (1), H4 (3), X1 (2), LAM-TUR (1), Orphan (16) | 74 |  | - | *-* | - | - | - | - | (44) | (Zewdie et al., 2016) |
|  | 2013 | Sputum | Spoligotyping & MIRU-VNTR typing  | CAS-DELHI (95), ETH-3 (32), Haarlem (21), ETH-1 (19), ETH-H37Rv-Like (17), ETH-2 (9), LAM (8), URAL (8), TUR (5), X-type (3), S-Type (2), Beijing (1), Uganda-II (1), Undefined (23) | 244  |  | - | *-* | - | - | - | - | (45) | (Tessema et al., 2013) |
|  | 2013 | Sputum  | Spoligotyping  | T1 (73), T3-ETH (19), CAS1-DELHI (38), CAS (15), U (37), T3 (11), T2 (11), H3 (20), H1(1), U (Likely-H) (4), U (Likely-T3) (1), Family-34 (3), Family-24 (1), CAS-KILI (7), LAM9 (2), T4 (3), LAM-1, 2, 6, or 9 (1), LAM8 (3), LAM7-TUR (4), EAI4 (2), EAI 1 (1), Family 36 (3), H2 (1), LAM & S/Convergent (5), Beijing (1) | 237 |  | - | *-* | - | - | - | - | (46) | (Yimer et al., 2013) |
|  | 2016  | Sputum  | MiSeq Whole Gene and Small Genome Sequencer (Illumina, USA)  | Lineage 7(30) | 30  |  | - | *-* | - | - | - | - | (47) | (Yimer et al., 2016) |
|  | 2015 | Sputum  | Spoligotyping & MIRU-VNTR typing  | CAS (60), Lineage 7 (36), Haarlem (35), NW-ETH3 (24), NW-ETH1 (15), NW-ETH2 (8), TUR (16), URAL (3), Beijing (1), LAM (1), NEW-1 (1), S (1), NW-ETH4 (5), LAM (1), Undefine (23) | 231 |  | - | *-* | - | - | - | - | (48) | (Yimer et al., 2015) |
|  | 2018 | Lymph node aspirates | Spoligotyping | T3-ETH (13), T (18), CAS (13), H (9), F33 (1), F36 (1), LAM9 (5) | 60 (6) | 60 | 10 | *rpo*B*:* S531L (4), H526Y (1); *kat*G*:* S315T2 (1), S315T1 (5) | GenoType®MTBDR*plus* | RIF(0), INH (1) | 5 | - | (49) | (Zewdie et al., 2018) |
|  | 2015  | lymph node aspirates | Spoligotyping & MIRU-VNTR | CAS-DELHI lineage (76), ETH-1(19), ETH-3 (17), ETH-H37Rv-like (16), ETH-2 (15), Haarlem (15), URAL (7), Uganda (4), LAM (4), S-type (3), X-type (2), TUR (1), EAI (1), Beijing (1) | 196 |  | - | *-* | - | - | - | - | (50) | (Biadglegne et al., 2015) |
|  | 2014  | lymph node aspirates | - | - | 29 (3) | 29 | 10.3 | *rpo*B*:* S531L (2), #WT3 (deletion) (1) | GeneXpertMTB/RIF assay & GenoType®MTBDR*plus* assay | RIF (3) | - | - | (51) | Biadglegne et al., 2014) |
|  | 2013 | lymph node aspirates | Spoligotyping  | H37Rv (2), *M. bovis* BCG (2), T3 (6), Family-34 (1), Family-33 (15), CAS (2), T1 (18), H3 (1) | 36 |  | - | *-* | - | - | - | - | (52) | (Garedew et al., 2013a) |
|  | 2013 | Sputum  | Spoligotyping  | H1 (1), H3 (1), LAM9 (2), T1 (34), T3 (20), X1 (10), CAS (13), Family-33 (9), Family-36 (5) | 99 |  | - | *-* | - | - | - | - | (53) | (Garedew et al., 2013b) |
|  | 2015 | Sputum & fine needle aspirate | Spoligotyping  | Euro-American lineage (22), Indo-Oceanic lineage (9) | 34  |  | - | *-* | - | - | - | - | (54) | (Gebrezgabiher et al., 2015) |
|  | 2015 | Sputum  | Spoligotyping  | SIT53 (15), SIT149 (11), SIT37 (9), SIT26 (3), SIT119 (3), SIT910 (3), SIT247 (3), SIT21 (2), SIT289 (2), SIT777 (2) | 91 |  | - | *-* | - | - | - | - | (55) | (Getahun et al., 2015) |
|  | 2013  | Sputum  | Spoligotyping  | Family-33 (18), Family-34 (1), T1 (27), MANU-2 (19), MANU-1(1), H3 (2), H4(1), EAI1-SOM (2), T3-ETH (27), CAS1-KILI (32), CAS1-DEHI (9), CAS (12), EAI4 (1), EAI5 (1), T3 (7) | 183 |  | - | *-* | - | - | - | - | (56) | (Diriba et al., 2013) |
|  | 2013 | Sputum  | Spoligotyping  | H3 (14), T1 (31), T3 (12), S (1), CAS (37), Family-36 (11), Family-33 (6), LAM9 (3), X2 (1), H37Rv (1), T4 (1) | 118 |  | - | *-* | - | - | - | - | (57) | (Debebe et al., 2014) |
|  | 2012 | Sputum  | Spoligotyping  | H4 (2), CASI-DELHI (1), T3(1), T3-ETH (1), T1 (2), H3-T3 (1) | 17 |  | - | *-* | - | - | - | - | (58) | (Deribew et al., 2012) |
|  | 2013 | Sputum & Lymph node-aspirate | Spoligotyping, MIRU-VNTR, lineage-specific-SNP analysis | T3-ETH (150), CAS1 (175), T1 (98), T3 (61), LAM7-TUR (17), LAM3 (16) | 964 |  | - | *-* | - | - | - | - | (59) | (Firdessa et al., 2013) |
|  | 2016 | Sputum  | Spoligotyping &MIRU-VNTR | Lineage-7 (‘Aethiops vetus’) (5) | 5 |  | - | *-* | - | - | - | - | (60) | (Nebenzahl-Guimaraes et al., 2016) |
|  | 2018 | Sputum  | Spoligotyping &MIRU-VNTR typing | Lineage-1 (7), lineage-3 (41), lineage -4(88), lineage-7 (25) | 161(14) | 161 | 8.7 | *rpoB: S531L(7); katG: C15T (12)* | MTBDRplus | RIF (2), INH (7) | 5 | - | (61) | (Bekele et al., 2018) |
| **Gabon (1)**  | 2017  | Sputum | Spoligotyping & MIRU-VNTR typing  | LAM10-CAM (42), H3 (18), T1 (22), MANU2 (14), Beijing (5), LAM9(4), MANU-ancestor (4), LAM6 (2) | 124 (21) | 124 | 16.9 | *rpo*B: D516Y (6), S531L (6), S522T (1); *kat*G: S315T (14); *inh*A: C15T (8); *pnc*A: G97S (2), T135P (1), S88Stop (1); *gyr*A: D94G (1); *rps*L: K43R (1) | GenoType®MTBR*plus* assay,GeneXpertMTB/RIF assay | ǂRIF, ǂNH, ǂSTM, ǂFlQ[[11]](#footnote-11), ǂPZA, ǂCAP  | 18 | - | (62) | (Alame-Emane et al., 2017) |
| **Ghana (7)** | 2010 | Sputum  | IS6110 RFLP, Spoligotyping | West-AFRI-1 (51), West-AFRI-2 (14), *M. bovis* (1), *M.tuberculosis* strains (230) | 325 (262) | 325 | 80.6 | *kat*G: S315T (149), S315N (4), S315G (2), S315I (2), S315T/wt (2), A291T (1); *fabG1-inhA*: T8A (3), T8C (4), G9A(1), C15T (6), G19A/G (1), C34T(1), G47C (6); *ahp*C*:* C43-insertion (1), G48A (9), G48A/Ge (1), T49-insertion (1), C52T/C (1), T54-insertion (1), C81T (1), , *rpo*B: S531L (14), Q513P (1), D516V (4), S522L (1), H526D (2), H526Y (5), H526C (1), 526G-insertion (1), S531W (1), L533P (2), S522L (1),  | GenoType®MTBR*plus* assay | ǂINH, ǂRIF  | 45 |  |  (63)  |  (Homolka et al., 2010)  |
|  | 2017 | Sputum  | - | - | 165 (31) | 165 | 18.8 | *rpo*B: D516V (6), S531L (2), H526Y (3), WT7 (526–529) (1), WT3 (513–517 )(3), WT8 (530–533) (2); *inh*A: T8C (6), C15T (5); *kat*G: S315T1 (15), S315T (24) | GenoType®MTBDR*plus* | RIF (2), INH (18) | 11 | - | (64) | (Addo et al., 2017) |
|  | 2016 | Sputum  | Spoligotyping  | EAI (36), Beijing (77), CAS-DELHI (23), Cameroon (1151), Ghana (341), Haarlem (119), H37Rv-like (2), LAM (37), S (3), Uganda-I (38), Uganda-II (45), West AFR-1(316), West AFR-2 (178), BOVIS-1-BCG (2), BOVIS-1 (5), BOVIS (8) | 2551 |  | - | *-* | - | - | - | - | (65) | (Yeboah-Manu et al., 2016) |
|  | 2011 | Sputum  | Spoligotyping  | Cameroon (51), Beijing (4), EAI (4), Ghana (22), Haarlem (15), LAM (2), S (2), Uganda I (4), X3(9), X (1), West AFRI-1 (26), West AFR-2 (5) | 162 |  | - | *-* | - | - | - | - | (66) | (Yeboah-Manu et al., 2011) |
|  | 2016 | Sputum | Spoligotyping  | Beijing (2), Cameroon (58), CAS-DELHI (1), EAI (2), Ghana (50), Haarlem (7), LAM (1), *M. bovis* (2), Uganda-I (4), West AFR-1 (24), West AFR-2 (6), Undefined (6) | 1490(161) | 1490 | 10.8 | *rpo*B*:* Q432P (2), Q432K (1), I491S (1), D435V (11), D435Y (1), S441L (1), H445R (2), H445C (2), H445D (2), H445Y (1), S450L (28); *rpo*C*:* G332R (4), V483G (6); *inh*A*:* G204D (32), V78A (3); *ahpC pro:* C54T (2), G88A (2), G142A (1), *inh*A *pro*: G102A (16), C15T (8), T8C (6), G47C (1), *ndh:* V117I (9), G137G (1), K32R (3);  *kat*G*:* S315T (142) | Shotgun sequencing  | RIF (10), INH (111) | 40 | - | (67) | (Otchere et al., 2016) |
|  | 2015 | Sputum  | - | - | 525 (59) | 525 | 11.2 | *rpoB:* S388L & S450L (1), Q409R & S450L (1), S450L (5), H445Y (5), H445D (2), H445R (1), D435V (1); *kat*G*:* S315T & P241P (1), S315T (40), S315N, I317V & P241P (1), S315T & L378L (1)*; inh*A *pro*: T8C (2), C15T (4), G47C (5), G102C (5) | GenoType®MTBR*plus* assay | INH (43), RIF (8) | 8 | - | (68) | (Asante-Poku et al., 2015) |
|  | 2018 | Sputum  | Spoligotyping & MIRU-VNTR typing  | Lineag 1 (38), lineage 2 (65), lineage 3(26), lineage 4[( Cameron(1046), Ghana(376), Haarlem (156), LAM(50), Uganda(40)], lineage 5 (289), Lineage 6(150) | 2309 |  | - | *-* | - | - | - | - | (69) | (Asare et al., 2018) |
| **Guinea (1)** | 2015 | Sputum  | Spoligotyping  | Family-34 (14), EAI (5), Beijing (8), CAS (2), LAM (23), LAM10-CAM (13), Haarlem (32), T-clade (60), S-clade (4), X-clade (6), U-clade (8), MAF WA-1 (3), MAF WA-2 (6) | 184 |  | - | - | - | - | - | - | (70) | (Ejo et al., 2015) |
| **Guinea-Bissau (2)** | 2015 | Sputum  | Spoligotyping & MIRU-VNTR | LAM9 (2), Beijing (6) | 100 (9) | 100 | 9 | *rpo*B: S531L (9) | GeneXpert system & GeneXpertMTB/RIF assay, & INNO-LiPA Rif | ǂINH, ǂRIF | 8 | - | (71) | (Rabna et al., 2015) |
|  | 2011 | Sputum  | Spoligotyping & IS6110 RFLP analysis | AFRI-1 (194), AFRI-3 (1), LAM9 (43), LAM1 (14), LAM4 (9), LAM5 (3), LAM2 (2), LAM3 (2), LAM10-CAM (2), T1 (41), T (8), T5 (3), T2 (1), H1 (22), H3 (15), EAI5 (20), EAI-SOM (4), EAI6-BGD (1), Beijing (7), X2 (2), X1 (2), MANU-2 (2), MANU-1 (1), MANU-ancestor (1), CAS1-DELHI (2) | 414  |  | - | - | - | - | - | - | (72) | (Groenheit et al., 2011) |
| **Madagascar (1)**  | 2017 | Sputum  | Spoligotyping & MIRU-VNTR typing. | Beijing (31), EAI (23), CAS (23), Haarlem (19), LAM (17), T (45) | 158 |  | - | *-* | - | - | - | - | (73) | (Rasoahanitralisoa et al., 2017) |
| **Malawi (3)**  | 2017  | Sputum  | - | - | 995 (64) | 995 | 6.4 | *rpo*B*:* D516V (6), H526D (1), H526Y (11), H526R (2), L511P (1), Q513E (2), S512T (1), S513L (1), S522L (1), S531L (10), S531Y (1), | GeneXpertMTB/RIF assay, ABI 3700, (Applied Biosystems, Foster City, California, United States) | ǂRIF | - | - | (74) | (Chikaonda et al., 2017) |
|  | 2010 | Sputum  | IS6110-RFLP, Spoligotyping, PCR-based technique, & MIRU-VNTR typing | Beijing (17), CAS1-DELHI (12), CAS1-KILI (44), CAS-Other (3), EAI1-SOM (15), EAI5 (28), EAI5 or EAI3 (2), EAI-Other (10), H1 (2), H2(1), Haarlem-Other (1), LAM1 (10), LAM2 (1), LAM3/S (2), LAM4 (3), LAM9 (4), LAM11-ZWE (103), LAM-Other (43), MANU1 (6), T1 (21), T2 (5), T2-T3 (13), T-Others (8), X1 (3), X1-LAM9 (1), X3 (2) | 377 |  | - | *-* | - | - | - | - | (75) | (Mallard et al., 2010) |
|  | 2008 | Sputum  | Spoligotyping & IS6110 RFLP | SIT59 (32), SIT129 (8), SIT21 (11), SIT53 (8), Beijing (7) | 682 |  | - | *-* | - | - | - | - | (76) | (Glynn et al., 2008) |
| **Mali (2)**  | 2012 | Sputum  | Spoligotyping | T1 (47), LAM10 (13), West AFR-2 (35), Beijing (2), CAS (2), S (1), X3 (2), X1 (1), T4 (1), T2 (2), EAI5 (3), EAI2 (1), H37Rv (1), H1 (2), H3 (4), LAM1 (1), LAM7 (1), LAM8 (1), LAM9 (3), *M.Bovis*-BCG (1) | 126 |  | - | *-* | - | - | - | - | (77) | (Traore et al., 2012) |
|  | 2017 | Sputum  | Spoligotyping  | CAS (8), Beijing (8), EAI2 (2), EAI3 (1), EAI5 (11), Family-33 (31), H37Rv (11), H1( 10), H3 (17), H2 (1), LAM1 (4), LAM10 (68), LAM7 (2), LAM8 (3), LAM9 (20), MAF WA-2 (75), MAF WA-1 (4), S (4), T1 (142), T2 (5), T3 (2), T4 (3), X1 (5), X3 (4), *M.bovis*-BCG (4) | 445 |  | - | *-* | - | - | - | - | (78) | (Togo et al., 2017) |
| **Morocco (7)** | 2009 | Sputum | - | - | 199 (74) | 199 | 37.2 | *kat*G: S315 (51); *inhp*-15 (2); *embB306* (11); rrs512 (2) *rpsL43* (7), *rpsL88A* (1) | PCR probe-based assay | ǂINH, ǂSTM , ǂEMB | - |  | (79) | (Chaoui et al., 2009) |
|  | 2009 | Sputum | - | - | 194 (47) | 194 | 24.2 | *rpo*B: S531L (25), S531W (3), H526T (4), S522L (2), L511P (1), D516Y (1), D516V (2), N519–520P∆ (1), F514–515L ∆ (1) | ABI Prism 310 DNA Sequencer (Applied Biosystems, Foster City, CA, USA) | ǂRIF | - |  |  (80) | (Kourout et al., 2009) |
|  | 2017  | Sputum  | - | - | 524 (155) | 524 | 29.6 | *gyr*A: A90V (6), D94N (2), D94Y (2), D94G (7), D94H (2); *rrs*: A1401G (1)  | GenoType®MTBR*plus* V1.0 assay | ǂINH, ǂRIF, ǂOFL, ǂKAM, ǂAMK | 155 | - | (81) | (Ennassiri et al., 2017) |
|  | 2012 | Sputum  | Spoligotyping & MIRU-VNTR typing  | Beijing (5), H2 (4), T1 (71), CAS1-DELHI (1), T (34), LAM3 (22), S (23), H3 (78), T3 (3), T4 (2), LAM9 (188), T5 (4), H1 (53), T5-Madrid-2 (4), LAM4 (13), LAM10-CAM (4), LAM6 (3), LAM5 (9), LAM3 (6), LAM12-Madrid-1 (1), T2 (1), H37Rv (1), BOV-1 (2), BOV-4-CAPRAE (1), LAM1 (7), LAM (10), H (1) | 592 |  | - | - | - | - | - | - | (82) | (Lahlou et al., 2012) |
|  | 2018 | Sputum  | - | - | 70 (47) | 70 | 67.1 | *kat*G: S315T (34); *inh*A-pro: C15T (10); *rpo*B: S531L (23), H526D (8), D516V (4) | GenoType®MTBR*plus* assay | RIF (9), INH (12) | 26 | - | (83) | (Karimi et al., 2018) |
|  | 2015  | Sputum (induced, bronchial wash, bronchial aspirations & pleural fluid & gastric liquid) | Spoligotyping & MIRU-VNTR typing | LAM3 (8), LAM5 (1), LAM6 (1), LAM9 (67), CAM alias Cameroon (4), H1 (11); H3 (29), T1 (24), T2-S (2), Beijing (5), U-Clade (4), S-Clade (2) | 168 |  | - | - | - | - | - | - | (84) | (Bouklata et al., 2015) |
|  | 2013 | Sputum  | MIRU-VNTR & Spoligotyping | LAM1 (2), LAM3 (9), LAM4 (7), LAM5 (6), LAM9 (68), LAM10-CAM (4), H1 (18), H2 (2), H3 (35), T1 (37), T2 (3), T3 (4), T5-Madrid2 (3), S-Clade (2)  | 219  |  | - | - | - | - | - | - | (85) | (Chaoui et al., 2014) |
| **Mozambique (6)** | 2016 | Sputum  | - | - | 155 (55) | 155 | 35.5 | *rpo*B: S531(10), H526Y (6), D516V (1), H526D (1); *inh*A-pro: C15T (5); *emb*B: M306I (3), M306V (2); *gyr*A: A90V (7), D94G (2), D94N/Y (1); *kat*G: S315T (32) | GenoType®MTBDR*sl* & GenoType®MTBDR*plus* | RIF (2), INH (13), EMB (9), FLQ (6) | 25 |  | (86) | (Namburete et al., 2016) |
|  | 2016  | Sputum  | - | - | 155 (38) | 155 | 24.5 | *kat*G*:* S315T (32*); inhA:*C15T(4) | GenoType®MTBDR*plus* | ǂRIF, INH (13) | 25 | - | (87) | (Bollela et al., 2016) |
|  | 2015 | Lymph node Aspirates, Axillary site, Inguinal region, breast  | Spoligotyping & MIRU-VNTR typing  | Beijing (5), LAM9 (6), EAI1-SOM (15), T1 (4), EAI6-BGD1 (2), LAM3 (2), S (1), LAM4 (1), T5-RUS1 (1), CAS1-DELHI (1), EAI5 (2), X1 (1), H3 (2) | 49 |  | - | *-* | - | - | - | - | (88) | (Viegas et al., 2015) |
|  | 2010 | Sputum  | Spoligotyping  | EAI1-SOM (69), EAI6-BGD (38), EAI5 (24), EAI3-ND (1), Beijing (30), Beijing -like (1), CAS1-KILI (7), CAS1-DELHI (3), CAS-LIKE (1), MANU-1 (2), MANU-2 (1), Beijing/Euro-American (2), LAM11-ZWE (59), LAM9 (44), LAM3 (24), LAM1 (16), LAM4 (13), LAM10-CAM (4), LAM5 (3), LAM6 (2), T2 (20), T1 (19), T5 (6), T3 (5), T (1), T4-CEU (1), X3 (11), X1 (2), H1 (7), H3 (7), S (8) | 445 |  | - | *-* | - | - | - | - | (89) | (Viegas et al., 2010) |
|  | 2014  | Sputum  | MIRU-VNTR typing  | EAI-Family (41), LAM, Haarlem (4), S (3), X (2), Uganda-Family (2), Cameroon (1), CAS-Family (3) | 67 |  | - | *-* | - | - | - | - | (90) | (Saifodine et al., 2014) |
|  | 2018 | Sputum  | WGS [( Illumina MiSeq SequencingSystem MiSeqV2-500 cycles (Illumina, San Diego, CA, USA)) | Linege-4 (European American) (9), Lineage-1 (East African/Indian ocean (2), Lineage-2 (Beijing/East Asian)(1), Lineage-3 (Delhi(Central Asian)(1) | 13 (13) | 13 | 100 | *rpoB:* Ser450Leu(3), Val170phe(2), His445Tyr(3); *katG*:Ser315Thr (9), KasAGly269ser(1); pncA: Lys96Arg(2), Arg154Gly(1), Leu19Arg(2); *embB*: Met306Val(2), Met306Ile(2), Gln497Arg(3), Glu378Ala (2); *embC*; Thr270Ille(2); *rpsL*: Lys43Arg(7), Lys88Arg(1); *gyrA*: Ala90Val(3) | MTBDR*plus &* MTBDR*sl,*WGS [( Illumina MiSeq SequencingSystem MiSeqV2-500 cycles (Illumina, San Diego, CA, USA)) | RPMǂ, INHǂ, EMBǂ, PZAǂ, FLQǂ, | - | - | (91) | (Feliciano et al., 2018) |
| **Nigeria (8)**  | 2011  | Sputum  | Spoligotyping | T5 (1), T1 (31), LAM10-CAM (71), H3 (3), AFRI-2 (19), AFRI-3 (8), LAM9 (2), AFRI-1 (2), EAI5 (2), T3 (2), LAM6 (1), LAM3 (1), BOV-1 (1), EAI (3) | 163  |  | - | *-* | - | - | - | - | (92) | (Cadmus et al., 2011) |
|  | 2012 | Sputum  | Spoligotyping  | LAM10-CAM (42), AFRI-2 (27), H1 (2), H3 (2) | 81 |  | - | *-* | - | - | - | - | (93) | (Thumamo et al., 2012) |
|  | 2010  | Sputum  | Spoligotyping  | LAM-10 (81), LAM5 (2), LAM8 (2), H3 (4), H1 (6), T1 (2), T2 (2), Family-23 (2), Family-33 (1), Famaily-35 (1), EAI 5 (2), X3 (5), *M. africanum* (1) | 111 |  | - | - | - | - | - | - | (94) | (Ani et al., 2010) |
|  | 2017 | Sputum  | WGS (MiSeq ((Illumina) | BOVIS (1), Cameroon-clade (39), Ghana Clade (4), Ghana Haarlem X-type (1), H37Rv (1), Haarlem (5), LAM (5), TUR (3), Uganda-Clade (6), West AFR-1(7) | 73(46)\* | 73 | 63.0 | *rpoB*: H445Y (2), S450L (32), S450W (3), D435Y (10), A286V (4), L430P (9), D435V (1), H445D (2), H445L (1), D747A (1), S452F (1); *inh*A-pro: C15T (3), C52T (1), G48A (2), G74A (1); *inh*A: I194T (2), I21T (1); *kat*G: P241P (20), S315N (2), I335V (1), L587P (2), S315T (28), A106V (2), A139P (1); *rps*L: K43R (11), K88T (2), A514C (1), S172R (1); *gid*B A138V (1), K16R (1); *emb*B: M306I (7), M306V (17), D328Y (1), D354A (1), Q497P (5), G406A (4), G406S (3), Q497K (1), Q497R (7), *emb*A-pro: C11A (1), C12T (3), D4N (1); *gyr*B: E501D (1); *gyr*A: A90V (1), D94A (1), D94G (4), D94H (1); *pnc*A: A7G (1), A102V (1), A146P (1), A161P (1), D12A (1), G162A (1), G17D (1), H57D (1), L120P (2), L172P (1), L27P (3), P54Q (2), P69L (1), Q141P (1), S67L (1), S67P (1), T135P (2), T142A (1), T160R (1), T76P (2), V125F (1),V128G (1),V180F (3), V180phe (1), W68R (1), T11C (1). | WGS-MiSeq Illumina (Illumina, Little Chesterford, UK) | ǂ*\**RIF, ǂ*\**INH, ǂ*\**STM, ǂ*\**PZA, ǂ*\**EBM, ǂ*\**CAN, ǂ*\**KAM, ǂ*\**OFL, ǂ*\**ETH | 43\* | - | (95) | (Senghore et al., 2017) |
|  | 2016 | Sputum  | Spoligotyping & MIRU-VNTR typing | H3 (8), T2 (6), T1 (12), LAM10-CAM (119), AFRI-1(1), AFRI-2 (21), MANU-ancestor (7), T (1), S (2), Undefined (4) | 180 |  | - | *-* | - | - | - | - | (96) | (Uzoewulu et al., 2016) |
|  | 2012 | Sputum  | Spoligotyping & MIRU-VNTR typing  | Beijing (1), BOVIS-1 (4), CAM (269), H3 (32), H3/T2 (2), LAM (2), LAM4 (1), T1 (8), T1-T2 (1), T2 (28), U (11), West AFR-1 (52), *Africanum*  (1) | 412 |  | - | *-* | - | - | - | - | (97) | (Lawson et al., 2012) |
|  | 2018 | Sputum  | Spoligotyping  | MANU-ancestor (3), T1 (84), EAI5 (3), T2 (12), H3 (9), U (20), CAM (283), CAM9 (6), X1 (3), T3 (1), H1 (1), AFRI-2 (79), AFRI-3 (8), T (4), CAS1-DEHLI (1), AFRI-1 (4), EAI2-MANILLA (1), BOV (1), BOV-1 (1), LAM3 (1), Beijing (1) | 549 |  | - | *-* | - | - | - | - | (98) | (Molina-Moya et al., 2018) |
|  | 2012 | Sputum  | - | - | 415 (19) | 205 | 9.3 | *rpo*B*:* H526Y (1), S531L (6), H526N (1), H526R (1), L511P (1), H526D (1), (L511P & D516A) (1); *kat*G*:* S315T (6); *inh*A*:* C15T (3) | GenoType®MTBDR*plus*, BigDye Terminator (v1.1; Applied Biosystems, Carls bad, CA) | RIF (6), INH (3) | 8 | - | (99) | (Dinic et al., 2012) |
| **Rwanda (2)** | 2007 | Sputum | - | - | 701 (4)\* | 701 | 0.6 | *gyr*A: T80A (3), N94A (1) | PCR amplification | FLQ (4)\* | - |  | (100) | (Umubyeyi et al., 2007) |
|  | 2012 | Sputum  | Spoligotyping  | T2 (76), T1(6), T2-Uganda (8), LAM1-ZWE (4), CAS1-DELHI (2), T2-T3 (1), H1 (1), LAM 3/S Convergent) (1), CAS-KILI (1), LAM-4 (1), LAM11-ZWE (1), CAS-DELHI (1) | 151 |  | - | *-* | - | - | - | - | (101) | (Gafirita et al., 2012) |
| **Sierra Leone (2)** | 2012 | Sputum | ABI 3130xl Genetic Analyzer (Applied Biosystems,CA, US) & the ABI Big Dye Terminator kit v.1.1 | West AFR-1 (6), West AFR-2 (17), Haarlem (14), LAM (15), EAI (4), Beijing (4), S-type (4), X-type (1), Cameroon (4), Sierra Leone-1 (7), Sierra Leone-2 (10) | 97 (50)  | 97 | 51.5 | *kat*G: S315T (23), D329 (frameshift) (1), A291T (1), W300C (1), R463L (2), Q471R (1), T302R (1); *inh*A: C15T (2): *ahp*C−57 (1); *rpo*B: S531L (8), H526Y (3), H526R (3), L533P(1), T481A (1); *rps*L: K43R (11), K88R (8); *emb*B: M306I (6), M306V (1), W332R (1), Q497K (1), Q1002R (1); *gid*B: L16R (6), A200E (3), A161A (1), A205A (9), A138V (1), G34A (1), Pro38 (1), V65G (1), G69A (2), G71R (1), V88A (1), Leu91Pro (1), G92D (3); *pnc*A: Y64 (tat/tata frameshift) (1), A146E (1), G162D (1), L172P (1), Q141 (cag/cagacggcgccag (insertion of 10-bp!frameshif) (1), I5 (atc/atcc frameshift) (1) | ABI 3130xl Genetic Analyzer (Applied Biosystems,CA, US) & the ABI Big Dye Terminator kit v.1.1  | \*INH (8), \*RIF (1), \*STM (14), ǂ*\**PZA, ǂ*\**EMB  | - | - | (102) | (Feuerriegel et al., 2012) |
|  | 2008  | Sputum  | Spoligotyping, MIRU-VNTRtyping & IS6110 fingerprinting, | Beijing (4), Cameroon (4), EAI(4), Haarlem (14), LAM (15), Sierra Leone-1(7), Sierra Leone-2 (10), S-type (4), X-type (1), West AFR-1 (6), West AFR-2 (17) | 97 |  | - | - | - | - | - | - | (103) | (Homolka et al., 2008) |
| **South Africa (46)** | 2017 | Sputum  | - | - | 451(451) | 451 | 100 | *pnc*A: Ins C after 456 (271), Ins A after 408 (7), ins G after 515 (23), L151S (19), Del G at 385 (2), Ins G after 312 (1), Ins G after 313 (1), Del T at 389 (1), Ins C after 456 (1), R154G (14), A102V (2), H71Y (10), S59P (3), G132A (3), G97D (1), Y34D (5), V139G (3),V130A (2), E15G (1), T47I (1), H51P (1),S65S (1), C104R (1), T153H (1), R154W (1) | PCR amplification, standard capillary sequencing of the*pnc*A promoter and coding DNA sequence | ǂPZA | 74 | 377 |  (104) | (Allana et al., 2017) |
|  | 2009  | Sputum  | Whole-genome sequencing (Illumina Paired-Endsequencing method (PE) | KZN-V4207, KZN-V2475, KZN-R506 | 11 (10) | 11 | 90.9 | *rpo*B: D435Y (1), M139I (1), T271M (1), D435G (1), L452P (1), I1106T (1), T403I (1); *rrs*: a1400g (1), L275P (1); *kat*G: S315T (2); *emb*B: M306V (1); *rib*A1: G251S (1); *pnc*A: G251S (1), P19L (1), +g in A152 (1), +2969973c (1), S82R (1), D64E (1), V188A (1), I256V (1): *gyr*A: A90V (1), I200V (1); *gid*B: (L50–P93) (1) | Whole-genome sequencing (Illumina Paired-Endsequencing method (PE) | INH (0), RIF (0), STM (0), OFL (0), KAN (0), EMB (0), | 10 | 9 | (105) | (Ioerger et al., 2009) |
|  | 2015 | Sputum  | IS6110-basedRFLP & Spoligotyping | LAM (263), Beijing (168), X-Family (129), T1–T4 (91) | 1,240 |  | - | - | - | - | - | - | (106) | (Mathema et al., 2015) |
|  | 2009 | Sputum  | Spoligotyping & MIRU-VNTR typing | T1 (56), Beijing (26), LAM3 (23), X2 (19), S (23), X3 (18), LAM9 (10), LAM11-ZWE (13), LAM4 (10), CAS1-KILI (5), LAM6 (4), X1 (10), H3-T3 (4), T2 (4), T5 (4), H3 (3), U (7), EAI1-SOM (3), LAM1 (1), H37Rv (1), T2-T3 (1), LAM10-CAM-S (1), MANU-2 (2), T4-CEU1 (1), X3-Variant (1), H1-Variant (1), H1 (1), LAM3/S-Variant (1) | 252 |  | - | - | - | - | - | - | (107) | (Stavrum et al., 2009) |
|  | 2012 | Sputum  | Spoligotyping & MIRU-VNTR typing  | Beijing (69), EAI1-SOM (78), T1 (49), S (36), LAM3 (12), LAM4 (10), LAM9 (17), LAM11-ZWE (14), LAM10-CAM (1), LAM & S/convergent (2), X1 (2), X2 (6), X3 (9), H1 (1), H3 (12), T2-S (2), T2-T3 (1), T3 (12), T3-ETH (1), MANU-1 (3), MANU-2 (1), Undefined (33) | 336 |  | - | - | - | - | - | - | (108) | (Said et al., 2012) |
|  | 2008 | Sputum  | Spoligotyping  | Beijing (14), LAM4 (3) LAM9 (2), EAI1-SOM (4), T1 (2), T2 (1), T3 (1), H1 (1), H3 (1), X3 (1), S (1), Undefined (10) | 41 |  | - | - | - | - | - | - | (109) | (Mlambo et al., 2008) |
|  | 2015 | Sputum  | - | - | 88 (33) | 88 | 37.5 | *pnc*A: A102V(1), C14R(2),D12G (2), D12G/D (3), D35Y/D(1) , L35R/L (1), D8N (2), D8Y (2), L35R (3), G97C (1), H71Y (1), K96STOP (1), L515S (2), L159P/L (1), T135P/T (1), R154G/R (1), R154G (2), S164P (1), S59P/S (1), A79V (1), Promoter mutation: T10 C (1), T12C (2), Ins G at pos 315(2), Ins G at pos 35(2), Del T at pos515(1), Ins T pos 360 (1) | Ion Torrent next-generation sequencing (NGS) (Life Technologies, Foster City, CA, USA) | ǂPZA  | - | - | (110) | (Maningi et al., 2015) |
|  | 2018 | Sputum  | Spoligotyping & MIRU-VNTR quadruplex typing kit | T (58), LAM (43), Beijing (34), X (28), S (19), H (8), MANU-2 (3), U (4), EAI1-SOM (1), H37Rv (1), Orphans (41) | 240 (220) | 240 | 91.7 | *rpo*B*:* S531L (26), H526Y (15), S526D/YSTOP (2),D516V (6), S531T (1), T525P (1), H526D (3), L533P (1), H526L (1), T480A (1), Q409R (1), S450L (1), S531W (2), S522L (2), Q253R (1), H256R (2), L511P/L STOP (1), DelC526 (1), V251F (2), V249M (1), V251Y (1), H526L/H (1), H526L/A (1), I572F/I STOP (2), S531L/S STOP (1); *kat*G: S315T (37), S315I (2), S315T/S STOP (1), R463L (17), S315N (3), DelCpos526 (1), W91R (2), A464L (1), S140G (1), S315R 1), Del2185G (1), I200T (1), P131R (1), Y98C (1), D381E (1), P232R (1), D1426R (1), del 1426G (1), P29S (1), M420T (1), P232A (2), S100A (1), Ins19A (1), F594S (1), Q88STOP (1), G699E (2), L378R (1), A122G/A (1), W477STOP (2), W412STOP (1), Ins576A (1), W198STOP (1), T380I (1), W198STOP (1), G299R/G STOP (1), E553K (1), G299S (1), R104W (1), DelGpos1284 (1), *emb*B: M306I (14), M306V (7), Q497R (3), T11Xaa (1), L17Xaa (1), G25Xaa (1), D456Xaa (1), M306Xaa (3), G406D (1), Q51P (1), D354A (1), G406Xaa (1), E378A (1), Y319S (1), Q139H (1); *pnc*A: W68G (1), D8N (2), W68STOP (1), -11A>R (1), F13L (1), W68R (1), C72Y (1), Ins A pos 193(4), A134R (1), L35R (4), Q10P (1), E37STOP (1), G97D (1), T100I (2), T159A (1), G108R (1), C14R (1), H71Xaa (2), T168Xaa (2), I6T (1), Q10Xaa (1), V163A (1), T153I (1), Del G pos 7 (1), Del G pos 391 (1), T76P (2), F106S (1), Leu4Ser (1), S164L (1), Ins G pos 392 (1), Ins G pos 39 3(1), I159A (1); *gyr*A: S91P (1), S95T (15), G668D (14), Q613E (10), Q21E (2), C254R (1), G247S (4), A90Xaa (1), S741P (1), V384A (1), L252R (1), D89Xaa (1); *rrs*: G1484T (2), G1403R (1), T1404Y (1), C492T (15), C517T (4), A514C (2), A1401R (1), G1260R (2), A1278W (2), C492T (1), C1445Y (1); *rps*L: K43R (9), K88R (2) | Illumina MiSeq Whole Genome Sequencing (WGS), GenoType®MTBDR*sl* V.2 assay, GenoType®MTBDRplus version 1 assay | RIF (44), INH (5), OFX (3), AMG (0), KAM (0), ǂEMB  | 171 | - | (111) | (Maningi et al., 2018) |
|  | 2017 | Sputum  | - | - | 97(97) | 97 | 100 | *rpo*B*:* S531L (46), D516V (27), H526Y (7), H526D (3); *kat*G*:* S315 T1 (32), T8A (8); *inhA:* C15T (14); *emb*B*:* M306 V (15), M306I (9); *gyr*A*:* A90V(9), S91P (1),D94G (3), D94A (1); *rrs:* A1401G (3), C1402T (2) | GenoType®MTBDR*plus* & GenoType®MTBD*Rsl* | RIF (43), INH (14), ǂOFL, ǂKAN, EMB (0) | 40 | 3 | (112) | (Maningi et al., 2017) |
|  | 2009  | Sputum  | RFLP-IS6110 transposable element | Beijing (57), LAM (27), Haarlem (10), X (23) | 157 |  | - | *-* | - | - | - | - | (113) | (Marais et al., 2009) |
|  | 2013  | Sputum  | Spoligotyping & 12-MIRU typing | Beijing (71), LAM4 (69), T1 (55), H3 (37), S (32), EAI1-SOM (37), X3 (20), LAM3 (16) | 434  |  | - | *-* | - | - | - | - | (114) | (Marais et al., 2013) |
|  | 2017  | Sputum  | Spoligotyping  | Beijing (32), CAS1-DELHI (4), S (21), X1 (7), T1 (33), LAM3-LAM6 (1), CAS1-KILI (3), LAM3 (21), LAM9 (10), T5 (1), H3 (3), T2 (2), MANU-2 (3), U (1), LAM11-ZWE (7), LAM4 (8), T2-T3 (3), BEIJING-LIKE (2), EAI1-SOM (4), X3 (4), CAS (3), LAM7 (2), T3 (1), LAM8 (10), T4 (3), X2 (1), EAI5 (4), LAM1 (1), Family 33 (4), EAI4 (3), *M. microti* (4)  | 215 |  | - | - | - | - | - | - | (115) | (Maguga-Phasha et al., 2017) |
|  | 2016  | Sputum  | Spoligotyping  | S (44), X2 (5), X3 (31), T (16), LAM (9), Beijing (8), Haarlem (7), EAI (4) | 124 (124) | 124 | 100 | *rrs*1400 (26), *rrs*900 (22), *rrs*500 (6), G878A (21); *eis* :(13); *tly*A (2), Rv0194 (2), Rv1258c (1) | GenoType®MTBDR*sl* | AMK (2), KAM (20), [[12]](#footnote-12)CAP (31) | - | 29 | (116) | (Malinga et al., 2016a) |
|  | 2015 | Sputum  | Spoligotyping  | Beijing (135), S (42), LAM4 (41), T1 (38), LAM3 (30), H3 (21), EAI1-SOM (17), X3 (16)  | 500  |  | - | - | - | - | - | - | (117) | (Kamudumuli et al., 2015) |
|  | 2011 | biopsy specimens  | Spoligotyping & MIRU-VNTR | Beijing (8), LAM3 (8), S (9), T3 (1), T4-CEU1 (2), T1 (5), T2 (1), MANU-2 (1), LAM4 (5), H1 (1), T2-T3 (2), X3 (1), H3 (1), X1 (1), LAMI1-ZWE (3) | 56 |  | - | - | - | - | - | - | (118) | (Cohen et al., 2011) |
|  | 2008  | Sputum  | - | - | 240 (240) | 240 | 100 | *rpo*B: D516V (68), H526D (60), S531L (1), S512T (1), M515H (1), D516V (1),Q517P (1), N518E (1), N519Q (1), T525H (1), H526D (1), R529P (1), L530P (1), S531L (1), A532R (1), L533R (1), *kat*G: S315T (95), S315N (70), S315I (17), S315R (8), S315T (5), T314P (20) | SCE2410 capillary sequencer (Spectrumedix) | \*INH (44), \*RIF (11), \*EBM (4), \*STM (7) | \*143 | - | (119) | (Green et al., 2008) |
|  | 2014  | Sputum  | Spoligotyping  | Beijing (33), LAM3/S (2), LAM3 (15), LAM9 (3), LAM4 (112), LAM1-LAM4 (1), LAM3-LAM6 (1), S (35), T3 (6), T4-CEU1 (1), T1 (39), T2 (1), X1 (1), X3 (2), H1 (2), H3 (4), H1-variant1 (2), CAS1-Kili (3), CAS1-DELHI (3), EAI-undefined (1), U (2), MANU-2 (2), EAI1-SOM (1), CAS (3) | 297 |  | - | - | - | - | - | - | (120) | (Gandhi et al., 2014) |
|  | 2017  | Sputum  | - | - | 268 (120)\* | 268 | 44.8 | *gyr*A: A90V (29), D94N (16), D94Y (16), S91P (9), D94A (7), D94G (25), D94H (9), G247S (2); *gyr*B: S274R (2), N499S (2), V457L (2); *rrs*: A1401G (48), G1401A (2); *eis*: C14T (8) | GenoType®MTBDR*sl* V.2.0 assay, WGS  | ǂOFX, ǂKAN, ǂAMK, ǂCAP |  | 27 | (121) | (Gardee et al., 2017) |
|  | 2012 | Sputum  | - | - | 256 (41) | 255 | 16.1 | *rpo*B: S516L (3), S531L (8); *inh*A: C15T (4); *kat*G: S315T (9) | GenoType®MTBR*plus* | ǂRIF, ǂINH  | 11 | - | (122) | (Dorman et al., 2012) |
|  | 2012 | Sputum & gastric aspirate | - | - | 18 (18) | 18 | 100 | *#rpo*B*(5)* | GenoType®MTBR*plus* | RIF (18) | - | - | (123) | (Dramowski et al., 2012) |
|  | 2012 | Sputum  | - | - | 26 (21) | 26 | 80.8 | *rpo*B: S531L (9), (S531L, V194I) (1), (S531L, Y645H) (1), H526D (1), (H526Y, S509R) (1), H526R (1), (D516G, L533P) (6), D516V (1); *pnc*A: C14R (3), A102V (1), Q122Stop (1), V139G (1), R154G (1), L172P (2); *kat*G: S315T (11), (S315T, R463L) (5); *gyr*A: (E21Q, D94G, S95T, G668D) (2), (E21Q, G88C, S95T, G688D) (1), (E21Q, D94Y, S95T, G668D) (1), (E21Q, A90V, S95T, G247S, G668D) (6); *rrs*: (A514C, A1401G) (1), A1401G (6) | Next-Generation sequencing (Ion Torrent) | ǂRIF, ǂINH, ǂFLQ, ǂKAM, ǂPZA  | 14 | 7 | (124) | (Daum et al., 2012) |
|  | 2016 | Sputum | Spoligotyping & IS6110 RFLP | Euro-American lineages-T2 ( 9), EuA-(T,X, H) (68), EuA-LAM (87), EuA-LAM9-T5 (45) EuA (27), EuA-LAM3 (7), Beijing (26) | 240 (240) | 240 | 100 | *gyr*A: D94G (32),A90V (26), D94A (14), D94Y (5), S91P (3), D89N (3), D94N (2), T267I (2), R392C (2), A74S (1), P102S (1), R128K (1), A288D (1), P604S (1); *gyr*B I310M (16), S700T (16),V340L (11), N538T (4), E78K (1), A453S (1), R485C (1), R485H (1), S486Y (1), N538D (1), T539A (1), E540D (1), D679A (1), A681P (1) | Illumina GAIIx device | ǂMOX, ǂOFL | - | - | (125) |  (Farhat et al., 2016) |
|  | 2016 | Sputum | IS6110 (RFLP) | Beijing (6), KZN (33), F28 (8), F28V (1), F11V (1) | 60 (43)\* | 60 | 71.7 | *kat*G*:* G473T (5), S315T (43), A1343 (1); *pnc*A*:* L139G (2), Y34D (6*); emb*B*:* M306V (37), Q506K (2); *rpo*B*:* L452P (24), S450L(9), Y564H (2), P454T (1), D435Y (1), H445L (1), I491M (1), D435G (26) | ABI Prism Big Dye Terminator cycle sequencing kit V3.1 (AppliedBiosystems) | ǂINH, ǂEMB, ǂRIF, ǂPZA | 15  | 28 | (126) | (Dookie et al., 2016) |
|  | 2016 | Sputum | - | - | 189 (189) | 189 | 100 | *rpo*B: S531L (105), H526Y (27), H526D (19), D516V (17), L533P (4), D516G-L533P (3), S531Q (1), H526P(1), H526R (1), H526L (1), Ins F at 514(1) | Sanger Sequencing | ǂRFB[[13]](#footnote-13), ǂRIF | 189 | - | (127) | (Rukasha et al., 2016) |
|  | 2015 | Sputum | - | - | 924 (924) | 924 | 100 | *rpo*B(777)#, *inh*A (306)#, C15T (165), T8A (67), *kat*G (772)# | GenoType®MTBDR*plus* assay | INH (91), RIF (21) | 694\* | 29\* | (128) | (Niehaus et al., 2015) |
|  | 2015 | Sputum |  - | - | 178 (154) | 178 | 86.5 | *rrs*: A1401G (154) | PCR-based analysis | ǂCAP | - | - | (129) | (Pietersen et al., 2015) |
|  | 2015 | Sputum | IS6110 (RFLP) | F15/LAM4/KZN genotype (35) | 52 (47) | 52 | 90.4 | *rrs*: A1401G (47) | GenoType®MTBD*Rsl* assay | ǂCAP | - | - | (130) | (O'Donnell et al., 2015) |
|  | 2014 | Sputum  | IS6110 RFLP | F15/LAM4/KZN (35), F28 (10), LAM3/F11 (1), Beijing-family (6) | 56 (30)\* | 56 | 53.6 | *gyr*A: E21Q (56), S95T (56), A90V (30) | ABI Prism BigDye® Terminator cycle-sequencing kit 3.1 (Thermo FisherScientific | ǂ*\**CIP[[14]](#footnote-14), ǂ*\**OFL, ǂ*\**MOX  | - | - | (131) | (Dookie et al., 2014) |
|  | 2014 | Sputum  | - | - | 190(190)\* | 190 | 100 | *rpo*B: Y42D (30), G52A (20), H87G (10), L92S (10), V441G (10), L450S (10), L457P (10); *kat*G: N293G (10), S293G (10), S315T (20), S315N (50), T315N (10), T315S (10), R463L (10); ,*rrs*: S2169A (120), R2201R (70), K2202E (80), Deletion2207 (50), *eis* (39)# | ABI 3130xl DNAsequencer (Applied Biosystems, UK |  ǂ*\**NH, ǂ*\**RIF,  ǂ*\**CAP,  ǂ*\**AMK, ǂ*\**EMB,  ǂ*\**STM,  ǂ*\**ETHIO, ǂ*\**OFL | \*189 | \*157 |  (132) | (Bhembe et al., 2014) |
|  | 2013 | Sputum | Spoligotyping  | Beijing (2321), LAM3 (398), LAM 4 (195), S (215), T1 (451) | 4667 (4161) | 4667 | 89.2 | *kat*G: S315T (222), *inh*A: G17T (153), C15T (48); *rpo*B: S531L (73), D616V (149); *pnc*A: C14R (58), 172G insertion (153), 153deletion (3), T100I (3), Y103STOP (3); *rrs*: A1401G (185), A513C (189); embB:M306I (224); *gyr*A: A90V (15), D94G (64), D94H (12), D94N (19) | PCR-based | ǂ\*NH, ǂ\*RIF, ǂ\*EMB, ǂ\*PZA, ǂ\*STM | 2319 | 196 | (133) | (Muller et al., 2013) |
|  | 2013 | Sputum | IS6110 RFLP & Spoligotyping  | Beijing (150), Low copy-clade lineage (CCC) (71), LAM (64), T (29), F28 (2), Haarlem (2), EAI (1), F26 (1)  | 340 (286)\* | 340 | 84.1 |  *rpo*B: S531L (127), 511CCG (4), 516GTC (18), 526CGC (2), 533CCG (6); *rpo*A: D57N (1), S165I (1), D190G (1), E319K (1); *rpo*C:G332R (3), F452C (1), D485Y (4), V483A (38), V483G (48), I491T (4), A542A (80), Q523E (1), H525Q (1), D19E (1), G594E (3), N698H (1), E110E (1), N698S (1), L901M (1), P1040R (1), G1071S (1), V1098G (1), Q1125H (1), Q1225H (1) | ABI PRISM DNA Sequencer model 377 (PerkinElmer) | \*RIF (53), \*INH (39),  | 101 | 48 | (134) | (de Vos et al., 2013) |
|  | 2013 | Sputum | Spoligotypes & IS6110 (RFLP) | Beijing (217), LAM3 (80), LAM4 (42), H (10), LAM-Other (8), MANU-2 (2), S (16), T (69), U (3), X (9), CAS (4) | 651 (334) | 342 | 97.7 | *kat*G: S315T (217); *rrs*: A1401G (143), A513C (209); *inh*A: G17A (162), *rpo*B: 516GTC (149); *emb*B: 306ATA (161); *pnc*A: Ins172G (159); *gyr*A: 94GGC (144) | PCR-based | ǂINH, ǂRIF, ǂEMB, ǂSTM, ǂOFL, ǂAMK, ǂCAP, ǂETH,  | 334 | 108 | (135) | (Klopper et al., 2013) |
|  | 2012 | Sputum  | - | - | 310 (50)\* | 50 | 100 | *rrs*: A1401G (5) | ABI3130XL genetic analyzer (Applied Biosystems) | ǂ\*AMK, ǂ\*CAP  | - | - |  (136) | (Sirgel et al., 2012a) |
|  | 2012 | Cattle milk  | - | - | 11 (10) | 11 | 90.9 | *rpo*B: H526Y (9), D516V (2), H526D (8), S531L (6); *inh*A T8A (10), C15T (6), A16G (6), T8C (6) | GenoType®MTBDR*plus* assay | ǂINH, ǂRIF | 10 | - |  (137) | (Silaigwana et al., 2012) |
|  | 2012 | Sputum  | - | - | 111 (67)\* | 111 | 60.4 | *emb*B: M306I (56), M306V (18), M306L (3) | ABI PRISM DNA sequencer (Applied Biosystems, Foster City, Calif., USA) | ǂ\*EMB | - | - |  (138) | (Sirgel et al., 2012b) |
|  | 2012 | Sputum  | - | - | 177 (52)\* | 177 | 29.4 | *gyr*A: T80S (1), G88C (1), D89G (1), A90V (12), S91P (3), D94A (7), D94G (17), D94N (6), A90V+D94G (2), D94N+D94G (2) | ABI PRISM DNA sequencer (AppliedBiosystems, Foster City, CA, USA) | ǂ\*OFL, ǂ\*MOX  | - | - |  (139) | (Sirgel et al., 2012c) |
|  | 2012 | Sputum | - | - | 171 (162) | 171 | 94.7 | *gy*rA A90V (34), D94A (14), D94G (52), D94N (15), D94Y (2), G88C (1), S91P (8), H70R (1), H52Q (1); #*pnc*A (29); *rrs* A1401G (5) | GenoType®MTBDR*plus* assay, DNA sequencing chromato-grams | ǂ\*OFL, ǂ\*AMK | - | - |  (140) | (Streicher et al., 2012) |
|  | 2010 | Sputum  | - | - | 288 (187) | 288 | 64.9 | *gyr*A: D94G (15), A90V (4); *rrs* :A1401G (34) | Multiplex allele-specific (MAS)-PCR assays | INH (41), RIF (10),ǂOFL, ǂKAN  | 136 | - | (141) | (Evans and Segal, 2010) |
|  | 2008 | Sputum | Spoligotyping & MIRU-VNTR typing | ST-18 (1), ST-21 (1), ST-34 (1), ST-71 (1), ST-92 (1), ST-137 (9), ST-719 (1), ST-926 (3). | 130 (42) | 130 | 32.3 | *pnc*A: D8N (1), D8Y (1), L34R (1), D12G (9), C14R (2), A20STOP (1), L35R (2), S59P (1), H71T (2), A79V (1), K96STOP (1), G97C (2), G97D (1), A102V (2), G132STOP (1), L151S (3), R154G (1), L159P (1) | ABI 377 automatic DNA sequencer (Applied Biosystems Inc., Foster, CA) | ǂ\*PZA  | - | - | (142) | (Mphahlele et al., 2008) |
|  | 2012 | Sputum  | Spoligotyping  | Beijing (1,665), CAS1-DELHI (8), CAS1-KILI (18), EAI1-SOM (59), EAI5 (2), EAI5 or EAI3 (2), H1 (17), H3 (115), H3-T3 (5), H4 (1), LAM1 (9), LAM1-LAM4 (1), LAM10-CAM-S (1), LAM11-ZWE (8), LAM2 (2), LAM 3 (193), LAM3 and S/convergent (6), LAM4 (293), LAM5 (1), LAM9 (33), MANU-1 (1), MANU-2 (15), S (188), T1 (310), T1-RUS2 (1), T2(7), T2-S (1), T2-T3 (8), T3 (38), T4-CEU1 (10), T5 (35), T5-RUS1 (2), U( 36), U (likely-H) (8), U (likely-H3) (3), X1 (181), X1-LAM9 (2), X2 ( 44), X3 (111) | 3,646 |  | - | - | - | - | - | - | (143) | (Chihota et al., 2012) |
|  | 2008  | Sputum  | - | - | 536 (133) | 536 | 24.8 | *rpo*B: D516V (10), H526Y (5), H526D (4), S531L (74); *kat*G: S315T1 (44), S315T2 (34); *inh*A: C15T (47), A16G (1) | GenoType®MTBDR*plus*  | RIF (16), INH (28) | 89 | - | (144) | (Barnard et al., 2008) |
|  | 2013  | Sputum  | Whole genome sequencing & MIRU-VNTR | Euro-American (46), East Asian (36), East African Indian (4), Indo Oceanic (4)  | 94 |  | - | *-* | - | - | - | - | (145) | (Bryant et al., 2013) |
|  | 2017 | Sputum  | Illumina GAIIx technology | Beijing isolate 46 (1), Beijing isolate 48 (1) | 2 |  | - | *-* | - | - | - | - | (146) | (Cornejo-Granados et al., 2017) |
|  | 2010 | Sputum  | Whole-Genome Sequencing | Beijing (14) | 14(14) | 14 | 100 | *rpo*B: D435V (3), S450L (7), H445Y (1); *emb*B: M306I (8), M306V (4); *kat*G: S315T (6), *inh*A: G17T (3), C15T (8), C15T, I194T (2); *pnc*A: C14R (3), +CL172 (3), D8N (1), Y103 (1), 881bp del (1), 8 bp del(1); *rrs*: A514C, C517T (1), A1401G (8), A514C (1); *rps*L: K43R(1); *eth*A: A381P (6); *gyr*A: D94G (3), D94A (3) | Whole-Genome Sequencing | ǂ\*RIF, \*INH (3), ǂ\*STM, ǂ\*EMB, ǂ\*PZA, ǂ\*CAN, ǂ\*KAM, ǂ\*AMK, ǂ\*ETM, ǂ\*OFL | 4 | 3 | (147) | (Ioerger et al., 2010) |
|  | 2010 | Sputum  | Whole genome sequencing  | RSA184 (1) , RSA114 (1) | 2(2) | 2 | 100 | rpo*B*: S450L (1), I491F (1); *kat*G S315T (1); *gyr*A: D94G (1) | Whole genome sequencing  | RIF, INH, OFL | - | \*2 | (148) | (Malinga et al., 2016b) |
|  | 2018 | Sputum  | - | - | 249 (40) | 249 |  16.1 | rpoB: Ile491Phe (37) | Xpert MTB/RIF & MTBDR*plus, MAS-PCR & Sanger sequencing* | ǂRIF, INHǂ | 37 | - | (149) | (Makhado et al., 2018) |
| **Swaziland (2)** | 2017 | Sputum  | - | - | 78 (78) | 78 | 100 | *rpoB*: I491F (39) | A real-time multiplex allele-specific PCR assay (MAS-PCR) | ǂRIF | 78 |  - | (150) | (Andre et al., 2017) |
|  | 2015 | Sputum  |  - |  | 125(125) | 125 | 100 | rpoB: Ile491Phe (38), D435F(1), D435F, N437D (3), D435V(1), G442R, I491F(1), H445D(7), H445L(6), H445Y(6), I491F, R552C(1), QF432–433del(1), S450L(58), S450W(1) | Xpert MTB/RIF | ǂRIF  | 125 | - | (151) | (Sanchez-Padilla et al., 2015) |
| **Sudan (5)** | 2017 | Sputum | - | - | 75 (58)\* | 75 | 77.3 | *rpo*B: S531L (12), H526D; *kat*G: S315T (10); *inh*A C15T (7); *rrs:* G892A (4), C222A (3), G885T (1), A 904G (2), A906G (1), T906A (1), G1400A (1), G1400C (1 T1238A(1) | Multiplex PCR, LPA, ABI Genetic Analyser(Applied Biosystems) | ǂ\*INH, ǂ\*RIF, ǂ\*STM, ǂ\*EMB  | - | 2 | (152) | (Sabeel et al., 2017) |
|  | 2015 | Sputum | - | - | 53(10) | 23 | 43.5 | *rpo*B: S512I R(1), R496Q (1), V475G (1), R528L (1), V498G (1), T488T (1) | Macrogen Inc. (Seoul, South Korea) | ǂRIF, ǂINH, ǂSTM, ǂEMB | - | - | (153) | (Khalid et al., 2015) |
|  | 2014 | Sputum  | - | - | 49 (49)\* | 49 | 100 |  *rpo*B: S531L (24), S531T (1), H526Y (5), H526L (2), H526C (1), D516V (3), L511P (1), 514-515F-insertion (2) | Macrogen Inc. (Seoul, South Korea) on a ABI3730XL DNA sequencer (Applied Biosystems, Foster City, USA). | ǂ\*RIF, ǂ\*INH, ǂ\*EM B, ǂ\*SM | 49  | - | (154) | (Elbir and Ibrahim, 2014) |
|  | 2011 | Sputum  | Spoligotyping  | CAS1-DELHI (126), T1 (16), Beijing/W (7), H3 (7), CAS (4), LAM7-TUR (3), U (3), T2 (3), S (1), LAM9 (2)  | 232 |  | - | - | - | - | - | - | (155) | (Sharaf Eldin et al., 2011) |
|  | 2013 | Sputum  | - | - | 60 (31)\* | 60 | 51.7 | #*rpo*B (15) | PRISM dye terminator cycle sequencing kit (Perkin Elmer) | \*RIF (1), \*INH (2), \*EMB (3), \*STM (6) | 18 | - | (156) | (Abdul-Aziz et al., 2013) |
| **Tanzania (9)** | 2013 | Sputum  | - | - | 22 (13)\* | 22 | 59.1 | #*kat*G (10); #*rpo*B (8); *pnc*A: V128G (2), E111stop (1), D49G (1), S179I (1), V169A (1); *emb*B: E378A (2), M306V (1), M306I (1), G406D (1), G406C (1), Y319C (1) | GenoType®MTBDRplus & GeneXpertMTB/RIFassay | ǂ\*INH, ǂ\*RIF, ǂ\*STM, ǂ\*EMB | 13 | - | (157)  | (Mpagama et al., 2013) |
|  | 2015 | Sputum  | Spoligotyping & MIRU-VNTR | Beijing (16), CAS1-KILI (55), CAS (2), CAS2 (1), EAI5 (22), EAI5 or EAI3 (4), EAI1-SOM (1), LAM11-ZWE (32), CAS1-DELHI (2), LAM6 (1), LAM9 (7), LAM3 & s/convergent (1), H1 (2), H3 (3), H3-T3 (1), MANU-2 (1), S (1), T1 (23), T2 (12), T2-T3 (1), T3 (2), T3-ETH (11), T2-Uganda (3), U (2), X2 (1) | 293 |  | - | - | - | - | - | - | (158) | (Mbugi et al., 2015) |
|  | 2014 | Sputum  | Spoligotyping &MIRU-VNTR typing | LAM11-ZWE (51), CAS-KILI (44), CAS (7), EAI2 (1), EAI4 (1), EAI5 (33), T1 (37), Family-33 (2), LAM8 (1), H1 (8), CAS1-DELH (15), CAS2 (2), Beijing (3), H3 (4), H37Rv (6), LAM1 (1), LAM10-CAM (2), LAM4 (2), LAM9 (6), T2 (7), T3 (4), T3-ETH (2), U (1), EAI5/ EAI3 (7) | 248 |  | - | - | - | - | - | - | (159) |  (Stavrum et al., 2014) |
|  | 2014 | Sputum | Spoligotyping & MIRU-VNTR typing  | LAM (55), CAS-DELHI (37), EAI (9), X (5), Tanzania-H37Rv-related (4), Beijing (4), Uganda-II (3), S (2), Haarlem (1) | 129  |  | - | - | - | - | - | - | (160) | (Olaru et al., 2015) |
|  | 2016  | Sputum  | Spoligotyping | Beijing (12), CAS (105), CAS1-DELHI (19), CAS1-KILI (78), CAS2 (2), CAS (or CAS-Like) (6), EAI (49), EAI1-SOM (3), EAI5 (39), EAI6-BGD1 (2), EAI8-MDG (2), EAI (or EAI-Like (3), Haarlem (7), H1 (2), H3 (5), LAM (43), LAM6 (2), LAM9 (9), LAM11-ZWE (32), MANU(10), MANU-ancestor (1), MANU-1 (2), MANU-2 (7), S (1), T (64), T1 (29), T2-uganda (19), T3 (4), T3-ETH (11), T (or T-Like) (1), X (1), X2 (1)  | 293 |  | - | - | - | - | - | - | (161) | (Mbugi et al., 2016) |
|  | 2014  | Sputum  | Spoligotyping  | CAS (15), CAS1-DELHI (27), CAS1-KILI (152), EAI1-SOM (6), EAI5 (37), EAI6 BGD (2), MANU-1 (1), MANU-2 (1), H1 (3), H3 (7), LAM11-ZWE (53), LAM10 -CAM (2), LAM3 (8), LAM4 (2), LAM4-LAM5 (2), LAM9 (18), T1 (34), T2 (3), T2-Uganda (6), TAN/T2-Uganda (13), T2-T3 (6), T3 (3), T3-ETH (1), T4-CEU1 (2) | 487 |  | - | - | - | - | - | - | (162) | (Mfinanga et al., 2014) |
|  | 2016  | Sputum  | Microarray-based-Spoligotyping, MIRU-VNTR typing  |  EAI (21), CAS (21), LAM (8), T (8), Beijing (2), S (1), MANU (3) | 80 |  | - | - | - | - | - | - | (163) | (Hoza et al., 2016) |
|  | 2018  | Sputum  | Spoligotyping & WGS  | T1 (1), T3 (1), T3-ETH (1), CAS1-DELHI (1), EAI5 (1), LAM11-ZWE (1) | 74 (6)  | 74 | 8.1 | *Mab*A*-inh*A; C15T (3); *kat*G: S315T (2), S315T+ M306V (1), S315T+S531L + M306I (1); *rpo*B: H526L (1), S531L (4); embB:M306I (1), M306V (1); *rps*L: K43R (2) | WGS (Illumina MiSeq) | INH (0), RIF (2), STM (1), EMB (2), ǂETH, PZA (0), FLQ (0), KAM (0), AMK (0), CAP(0) | 1 | - | (164) | (Kidenya et al., 2018) |
|  | 2007 | Sputum & bronchoalveolar lavage  | Spoligotyping  | CAS1-KILI (39), LAM11-ZWE (19), ND (12), EAI (8), Beijing (7), T-Undefined (6), CAS1-DELHI (5), T1 (5), LAM9 (5) | 130 (12)\* | 111 | 10.8 | *kat*G: S531L (4), #*rpo*B (4) | ABI Prism® 7000 Sequence Detection System (Applied Biosystems) | I\*INH(7), \*RIF(0), \*STM (3), ǂ\*EMB  | 3  | - | (165) | (Kibiki et al., 2007) |
| **Tunisia (4)** | 2010 | Sputum | - | - | 495 (4\*) | 495 | 0.8 | *gyr*A: S95T (4), I92M (1), A90L (1), G88G (1); *gyr*B: R516R (1), V530V (1), L531L (1) | ABI PRISM Dye terminator cycle sequencing ready reaction kit (Applied Biosystems, Paris, France | ǂ\*CIP | - | - | (166) | (Soudani et al., 2010) |
|  | 2007 | Sputum | - | - | 544 (10\*) | 544 | 1.8 | *rpo*B: S531W (4), S531L (3), H526C/S531A (3) | ABI PRISM Dye terminator cycle sequencing ready reaction kit (Applied Biosystems) | ǂ\*RIF, ǂ\*INH | 10\* | - | (167) | (Soudani et al., 2007) |
|  | 2011 | Sputum | - | - | 283 (28)\* | 283 | 9.9 |  *rpo*B: D516V (8), H526D (2), S531L (1); *kat*G: S315T (27); *inh*A: C15CT (1) | 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) | ǂ\*RIF, ǂ\*INHA  | 12 | - | (168) | (Ben Kahla et al., 2011) |
|  | 2008 | Sputum  | Spoligotyping  | H3 (119), H1 (41), H4 (1), LAM9 (95), T1 (71), T5 (1), T3 (5), T2 (2), LAM4 (15), LAM1 (1), LAM5 (4), LAM3 (2), S (10), U (3), LAM7-TUR (3), MANU-2 (2), X (1), EAI1 (1) | 379 |  | - | - | - | - | - | - | (169) | (Namouchi et al., 2008) |
| **Uganda (13)** | 2014 | Sputum  | - | - | 313 (12\*) | 313 | 3.8 | *rpo*B: S531L (7), Q513K (3), H526A (1), L511P (1) | GeneXpertMTB/RIF assay | RIF (1\*) | 11\* | - |  (170) | (Mboowa et al., 2014) |
|  | 2011 | Sputum  | Spoligotyping  | Uganda-type (74), CAS-DELHI (9), LAM (8), EAI (7), Cameroon-family (5), Ghana-family (3) | 125 (6) | 125 | 4.8 | *rpo*B: D516V (3), S531L (2), H526Y/D (1); *kat*G: S315T (3), # *inh*A (1) | GenoType®MTBR*plus* assay | ǂRIF, ǂINH | 2 | - | (171) | (Bazira et al., 2011) |
|  | 2008 | Sputum  | Spoligotyping  | Beijing (4), T2 (185), T2-Uganda (38), CAS1-KILI (12), ND (13), CAS2 (2), LAM6 (2), H3 (2), T1 (3), EAI5 (3), LAM11-ZWE (5), CAS (6), LAM3/S (6), T1-T2 (9), CAS1-DELHI (9), LAM9 (9) | 344 |  | - | - | - | - | - | - | (172) | (Asiimwe et al., 2008a) |
|  | 2016 | sputum | Whole Genome Sequencing  | Beijing (5), CAS-Delhi (18), LAM (11), S-type (7), T2-Uganda (36), X1 (6), T1 (1), T (2), H1 (2) | 90 (90) | 90 | 100 | *rpo*B: S531L (16), D516V (2), Q513L (1), D516Y (3), H526D (4), H526L (1), H526R (1), H526T (1), H526Y (2); *rpo*C: N698S (1), V483A (1); *kat*G: S315T (44), S315T+ahpC-48 G/A (1), S315T+fabG1.pro-15 C/T (1), S315N (2), S315R (2); fabG1: pro-8 T/C (1), pro-15C/T (9); *ahp*C: 48G/A (1); *emb*B: M306V (6), M306L (3), G406A (2), Q497R (1), M306V+G406D (1), M306I (1), *emb*B+*emb*A: G406D+embA.pro-12C/T (1), Q497R+M306I+embA.pro 12 C/T (1); *rps*L: K43R (7), K88R (2); *rrs*: A514C (1), C517T (1), 905 C-A (1), 906 A-G (1), G1484T+C1402A (1), C517T (2), A514C (1); *pnc*A: D12A (1), P54Q (1), D63G (1), F94L (1), K96R (1), H137R (1), R154G (1), 180F+T142R (1), V180F (3) | Whole Genome Sequencing  | \*RIF (5), \*INH (54), ǂ\*EMB ǂ\*STM ǂ\*KNM ǂ\*AMK ǂ\*CAP | 31\* | - | (173) | (Ssengooba et al., 2016) |
|  | 2015 | Sputum & gastric lavagesamples | RT-PCR SNP genotyping assay (LRPS) | Uganda-family (49), L4-Non-Uganda family (12), Linage 3 (8) | 69 |  | - | - | - | - | - | - | (174) | (Wampande et al., 2015) |
|  | 2015 | lymph node fine needle biopsy aspirates | Spoligotyping  | T2-Uganda (46), T1 (19), CAS1-Delhi (10), T2 (7), CAS-KILI (5), T (3), Beijing (3), MANU-3 (3), EAI5 (3), LAM11-ZWE (3), MANU-2 (2), T2or LAM3 (2), CAS2 (1), H1(1), T3-ETH (1), LAM3 (1), H3 (1), EAI3-IND (1), LAM9 (1), MANU-ancestor (1), Unknown (7) | 121 |  | - | - | - | - | - | - | (175) | (Wamala et al., 2015) |
|  | 2013 | Sputum  | Single NucleotidePolymorphic (SNP) markers by RT-PCR assay | Uganda-Family (1,092), non-Uganda (394), Lineage 3 (187) | 1,746 |  | - | - | - | - | - | - | (176) | (Wampande et al., 2013) |
|  | 2013 | Sputum & lymph node aspirates | Spoligotyping, MIRU-VNTR 15loci typing | T1 (5), T2-Uganda-I (12), T2-Uganda-II (18), T1-T2 (3), LAM11-ZWE (2), CAS1-KILI (2), CAS1-DEHLI (5), LAM3 (3), S (3), X2 (1), CAS (2), U (1) | 74  |  | - | - | - | - | - | - | (177) | (Muwonge et al., 2013) |
|  | 2014  | Sputum  | Spoligotyping  | T2 (85), T2-Uganda (142), T1(36), CAS (17), CAS1-DELHI (17), CAS1-KILI(15), LAM11-ZWE (12), LAM3/S convergent (11), S (9), LAM9 (8), H3(7), T2T3 (4), T2-ETH (4), CAS2 (1), EAI5 (4), Beijing (2), LAM4 (2), H4 (2), MANU-1 (2), MANU-2 (3), LAM6 (1), EA1ND (1) | 497  |  | - | - | - | - | - | - | (178) | (Lukoye et al., 2014) |
|  | 2008  | Sputum  | Spoligotyping and LSP analysis | T2 (101), T2-Uganda (38) | 344 |  | - | - | - | - | - | - | (179) | (Asiimwe et al., 2008b) |
|  | 2013  | Sputum  | Whole genome sequencing (Illumina HiSeq2000) | X1 (4), LAM3/S (5), CAS2 (7), T2 (8), CAS1-DELHI (7), LAM11-ZWE (6), T1(5), T (1), LAM3 (1), LAM9 (1), Beijing (1), CAS1-KILI (2), EA15 (1)  | 51 (44)\* | 47 | 93.6 | *rpo*B: S531L (21), S531STOP (1), H526D (3), H526R (1), H526Y (2), H526N (1), D516G (1), D516V (3), D516Y (1), Q513K (2), F505V (1); S450L (10), H445R (3); *kat*G: S315T (28), S315N (2), W191G (1); *pnc*A: G17D (1), D12A (2), L4S (1), D63G (1), G162D (1), S67P (1); *emb*B: M306I (14), M306V (6), M306L (1), G406D (4), G406S (1), Q497R (1); *gyr*A: S91P (1); *rps*L: K88R (3), K43R (2); *gid*: G30R (2) | Whole genome sequencing Illumina HiSeq2000 | ǂ\*RIF \*INH (2), ǂ\*EMB, ǂ\*PZA, ǂ\*STM, ǂ\*OFL  | 42\* | - | (180) | (Clark et al., 2013) |
|  | 2015 | Animal Bronchial Washes & Human Sputum  | Whole genome sequencing | *Mycobacterium* bovis BZ 31150 (1), *Mycobacterium* bovis B2 7505 (1) | 2 |  | - | *-* |  |  |  |  | (181) | (Wanzala et al., 2015) |
|  | 2018 | Sputum  | IS6110, MIRU-VNTR | Beijing(5), Delhi/CAS(12),EMA/lineage4(1), Ghana(2), Haarlem(6), LAM(7), NEW1(1), S(1), TURK(1), Uganda I (5), Uganda II (16), URAL (1) | 97(57) | 97 | 58.8 | *rpoB:* Ser531Leu(18), His526Tyr(12), Asp516Val(4), Ser531Leu, His526Tyr, Asp516Val combined(34), Leu511Pro(2), Glu513Lys(1); *katG*: Ser315Thr (38); *inhA*: C(-15)T(4), T(-8)C(2), Ser315Thr, C(-15)T, T(-8)C combined(40), A(-7)C(1), G(-116)A(1), A(-255)C(1), C(-305)T(1).  | Sanger DNA sequencing  |  INH (12), RIF (7) | 38 | - | (182) | (Kigozi et al., 2018) |
| **Zambia (2)** | 2018 | Sputum  | Spoligotyping  | X2 (2), LAMI 1-ZWE (11), T1 (9), T2 (1), S (1), LAM9 (1), CASI-KILI (16), CAS-DELHI (1) | 122 (21) | 122 | 17.2 | *pnc*A*:* Q10R (1), L35R (7), H43P (2), D49G (2), H51D (1), P56S (1), S65S (17), C72R (1), D80N (1), L85P (1), G97A (1), G105R (1), W119C (1), V128G (1), R154G (2), A171V (1) | BigDaye® terminator version 3.1cycle sequence reaction kit & ABI 3130 genetic analyzer (Applied Biosystems, Foster, CA, USA) | \*PZM (4) | - | - | (183) | (Bwalya et al., 2018) |
|  | 2010 | Sputum  | Spoligotyping & MIRU-VNTR typing  | LAM11-ZWE (100), LAM4 (2), LAM9 (10), T1 (35), T2 (1), X1 (4), H3 (1), S (1), U (1), T2-T3(1), X2(12), CAS (1), H1(2), CAS1-KILI (1), EAI5 or EAI3 (2) | 273 |  | - | *-* | - | - | - | - | (184) | (Mulenga et al., 2010) |
| **Zimbabwe (2)**  | 2007  | Sputum  | Spoligotyping & IS6110 genotyping  | Strains the Southern Africa-1 (SAF1) family, Spoligotypes (ST816) (3), ST412 (1), ST753 (1), ST84 (1), ST811 (14), ST813 (3), ST814 (1), ST815 (20), ST59 (36), ST42 (116) | 246 |  | - | *-* | - | - | - | - | (185) | (Chihota et al., 2007) |
|  | 2017 | Sputum  | - | - | 92(92\*) | 92 | 100 | *rpo*B: G507S (1), T508A (1), T508N (1), L511P (3), L511V (3), S512N (2), Q513del (1), F514del (2), M515del (3), D516del (8), D516G (8), D516Y (8), N518del (3), N518H (3), N519del (1), P520P (2), P520T (2), L524L (1), H526del (4), H526D (4), H526L (4), R528H (2), R529Q (1), S531L (25), S531W (25), S531F (25), L533P (1), A500D (1), A500T (1), I502T (2), K503N (10), K503K (10), E504K (28), F505L (2), F505F (2), F506L (1), Q490E (17), Q490Y (17), Q490Q (17), Q490STOP (17)E562D (9), E562A (9), E562Q (9), E562G(9), P564P (3), P564S (3), P564del (3), S553del (15), S553S (15), I572P (3), I572F (3), M471V (35), M471L (35), M471del (35), M471E (35), C559del (26), C559C (26), C559Y (26), R557Q (7), R557G (7), Y555H (34), Y555S (34), Y555F (34), Y555T (34), Y555S (34), Y555stop (34), A543T (12), A543Y (12), A543del (12), V547V (18),, V547del (18), P567T (10), P567del (10) G570D (10); *katG*: S303S (22), S303L (22), S303C (22) Y304stop (7), Y304inst (7), D311N (7), D311S (7), S315T (35), Y426Y (25), L427I (20), L430V (20), T435R (12), L436L (19), L436G (19) R463L (20), Q471Q (45), Q471Y (45), Q471H (45), L472K (42), L472Q (42), L472I (42), V473D (57), V473I (57), V473K (57), V473R (57), V473M (57), V473S (57), V473F (57), V473W (57), V473Y (57), V473V (57), V473G (57), V473stop (57), V473N (57), Del491 (18), G491D (18), G491V (18), G491V (18) | BioDye terminator v3.1 cycle sequencing kit (2ABI 3500XL, Applied Biosystems) | \*RIF, \*INH | 92 | - | (186) | (Takawira et al., 2017) |

***NB: #=*** *Nucleotide/ amino acid change not reported;* ǂ*=Monoresistance not reported;* ***\*****=Resistance based on phenotypic testing and sequencing;* ***MDR****=Multidrug resistance;* ***XDR****=Extensive drug resistance.*

**References**

1. Ifticene M, Kaidi S, Khechiba MM, Yala D, Boulahbal F. Genetic diversity of Mycobacterium tuberculosis strains isolated in Algeria: Results of spoligotyping. Int J Mycobacteriol. 2015;4(4):290-5.

2. Perdigao J, Clemente S, Ramos J, Masakidi P, Machado D, Silva C, et al. Genetic diversity, transmission dynamics, and drug resistance of Mycobacterium tuberculosis in Luanda, Angola. Int J Mycobacteriol. 2016;5 Suppl 1:S38-s9.

3. Affolabi D, Anyo G, Faihun F, Sanoussi N, Shamputa IC, Rigouts L, et al. First molecular epidemiological study of tuberculosis in Benin. Int J Tuberc Lung Dis. 2009;13(3):317-22.

4. Affolabi D, Sanoussi N, Codo S, Sogbo F, Wachinou P, Massou F, et al. First Insight into a Nationwide Genotypic Diversity of Mycobacterium tuberculosis among Previously Treated Pulmonary Tuberculosis Cases in Benin, West Africa. Can J Infect Dis Med Microbiol. 2017;2017:3276240.

5. Miotto P, Saleri N, Dembele M, Ouedraogo M, Badoum G, Pinsi G, et al. Molecular detection of rifampin and isoniazid resistance to guide chronic TB patient management in Burkina Faso. BMC Infect Dis. 2009;9:142.

6. Godreuil S, Torrea G, Terru D, Chevenet F, Diagbouga S, Supply P, et al. First molecular epidemiology study of Mycobacterium tuberculosis in Burkina Faso. J Clin Microbiol. 2007;45(3):921-7.

7. Shin SS, Modongo C, Baik Y, Allender C, Lemmer D, Colman RE, et al. Mixed Mycobacterium tuberculosis-Strain Infections Are Associated With Poor Treatment Outcomes Among Patients With Newly Diagnosed Tuberculosis, Independent of Pretreatment Heteroresistance. J Infect Dis. 2018;218(12):1974-82.

8. Tekwu EM, Sidze LK, Assam JP, Tedom JC, Tchatchouang S, Makafe GG, et al. Sequence analysis for detection of drug resistance in Mycobacterium tuberculosis complex isolates from the Central Region of Cameroon. BMC Microbiol. 2014;14:113.

9. Koro Koro F, Kamdem Simo Y, Piam FF, Noeske J, Gutierrez C, Kuaban C, et al. Population dynamics of tuberculous Bacilli in Cameroon as assessed by spoligotyping. J Clin Microbiol. 2013;51(1):299-302.

10. Koro Koro F, Um Boock A, Kaiyven AL, Noeske J, Gutierrez C, Kuaban C, et al. Genetic Structure and Drug Susceptibility Patterns of Mycobacterium tuberculosis Complex Strains Responsible of Human Pulmonary Tuberculosis in the Major Rearing Region in Cameroon. Biomed Res Int. 2016;2016:2904832.

11. Assam Assam JP, Penlap Beng V, Cho-Ngwa F, Toukam M, Ngoh AA, Kitavi M, et al. Mycobacterium tuberculosis is the causative agent of tuberculosis in the southern ecological zones of Cameroon, as shown by genetic analysis. BMC Infect Dis. 2013;13:431.

12. Ba Diallo A, Ossoga GW, Daneau G, Lo S, Ngandolo R, Djaibe CD, et al. Emergence and clonal transmission of multi-drug-resistant tuberculosis among patients in Chad. BMC Infect Dis. 2017;17(1):579.

13. Aubry A, Sougakoff W, Bodzongo P, Delcroix G, Armand S, Millot G, et al. First evaluation of drug-resistant Mycobacterium tuberculosis clinical isolates from Congo revealed misdetection of fluoroquinolone resistance by line probe assay due to a double substitution T80A-A90G in GyrA. PLoS One. 2014;9(4):e95083.

14. Malm S, Linguissi LS, Tekwu EM, Vouvoungui JC, Kohl TA, Beckert P, et al. New Mycobacterium tuberculosis Complex Sublineage, Brazzaville, Congo. Emerg Infect Dis. 2017;23(3):423-9.

15. N'Guessan K, Bakayoko AS, Ahui-Brou JM, Kouakou AO, Coulibaly B, Guei A, et al. Extensively drug-resistant Mycobacterium tuberculosis strains isolated in Cote d'Ivoire. Med Mal Infect. 2015;45(7):303-5.

16. N'Guessan Kouassi K, Riccardo A, Dutoziet Christian C, Andre G, Ferilaha C, Hortense SA, et al. Genotyping of mutations detected with GeneXpert. Int J Mycobacteriol. 2016;5(2):142-7.

17. N'Guessan KR, Dosso M, Ekaza E, Kouakou J, Jarlier V. Molecular characterisation of isoniazid-resistant Mycobacterium tuberculosis isolated from new cases in Lagunes region (Cote d'Ivoire). Int J Antimicrob Agents. 2008;31(5):498-500.

18. Blouin Y, Hauck Y, Soler C, Fabre M, Vong R, Dehan C, et al. Significance of the identification in the Horn of Africa of an exceptionally deep branching Mycobacterium tuberculosis clade. PLoS One. 2012;7(12):e52841.

19. Godreuil S, Renaud F, Choisy M, Depina J, Garnotel E, Morillon M, et al. Highly structured genetic diversity of the Mycobacterium tuberculosis population in Djibouti. Clin Microbiol Infect. 2010;16(7):1023-6.

20. Millan-Lou MI, Olle-Goig JE, Tortola MT, Martin C, Samper S. Mycobacterial diversity causing multi- and extensively drug-resistant tuberculosis in Djibouti, Horn of Africa. Int J Tuberc Lung Dis. 2016;20(2):150-3.

21. Abdel-Moein KA, Hamed O, Fouad H. Molecular detection of Mycobacterium tuberculosis in cattle and buffaloes: a cause for public health concern. Trop Anim Health Prod. 2016;48(8):1541-5.

22. Abbadi SH, Sameaa GA, Morlock G, Cooksey RC. Molecular identification of mutations associated with anti-tuberculosis drug resistance among strains of Mycobacterium tuberculosis. Int J Infect Dis. 2009;13(6):673-8.

23. Abdelaal A, El-Ghaffar HA, Zaghloul MH, El Mashad N, Badran E, Fathy A. Genotypic detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis strains by DNA sequencing: a randomized trial. Ann Clin Microbiol Antimicrob. 2009;8:4.

24. Helal ZH, Ashour MS, Eissa SA, Abd-Elatef G, Zozio T, Babapoor S, et al. Unexpectedly high proportion of ancestral Manu genotype Mycobacterium tuberculosis strains cultured from tuberculosis patients in Egypt. J Clin Microbiol. 2009;47(9):2794-801.

25. Diab HM, Nakajima C, Kotb SA, Mokhtar A, Khder NF, Abdelaal AS, et al. First insight into the genetic population structure of Mycobacterium tuberculosis isolated from pulmonary tuberculosis patients in Egypt. Tuberculosis (Edinb). 2016;96:13-20.

26. Meaza A, Kebede A, Yaregal Z, Dagne Z, Moga S, Yenew B, et al. Evaluation of genotype MTBDRplus VER 2.0 line probe assay for the detection of MDR-TB in smear positive and negative sputum samples. BMC Infect Dis. 2017;17(1):280.

27. Mekonnen D, Admassu A, Mulu W, Amor A, Benito A, Gelaye W, et al. Multidrug-resistant and heteroresistant Mycobacterium tuberculosis and associated gene mutations in Ethiopia. Int J Infect Dis. 2015;39:34-8.

28. Abate D, Tedla Y, Meressa D, Ameni G. Isoniazid and rifampicin resistance mutations and their effect on second-line anti-tuberculosis treatment. Int J Tuberc Lung Dis. 2014;18(8):946-51.

29. Biadglegne F, Tessema B, Rodloff AC, Sack U. Magnitude of gene mutations conferring drug resistance in mycobacterium tuberculosis isolates from lymph node aspirates in ethiopia. Int J Med Sci. 2013;10(11):1589-94.

30. Workalemahu B, Berg S, Tsegaye W, Abdissa A, Girma T, Abebe M, et al. Genotype diversity of Mycobacterium isolates from children in Jimma, Ethiopia. BMC Res Notes. 2013;6:352.

31. Tessema B, Beer J, Emmrich F, Sack U, Rodloff AC. Analysis of gene mutations associated with isoniazid, rifampicin and ethambutol resistance among Mycobacterium tuberculosis isolates from Ethiopia. BMC Infect Dis. 2012;12:37.

32. Ali S, Beckert P, Haileamlak A, Wieser A, Pritsch M, Heinrich N, et al. Drug resistance and population structure of M.tuberculosis isolates from prisons and communities in Ethiopia. BMC Infect Dis. 2016;16(1):687.

33. Nuru A, Mamo G, Worku A, Admasu A, Medhin G, Pieper R, et al. Genetic Diversity of Mycobacterium tuberculosis Complex Isolated from Tuberculosis Patients in Bahir Dar City and Its Surroundings, Northwest Ethiopia. Biomed Res Int. 2015;2015:174732.

34. Mihret A, Bekele Y, Aytenew M, Assefa Y, Abebe M, Wassie L, et al. Modern lineages of Mycobacterium tuberculosis in Addis Ababa, Ethiopia: implications for the tuberculosis control programe. Afr Health Sci. 2012;12(3):339-44.

35. Bedewi Omer Z, Mekonnen Y, Worku A, Zewde A, Medhin G, Mohammed T, et al. Evaluation of the GenoType MTBDRplus assay for detection of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis isolates in central Ethiopia. Int J Mycobacteriol. 2016;5(4):475-81.

36. Bedewi Z, Worku A, Mekonnen Y, Yimer G, Medhin G, Mamo G, et al. Molecular typing of Mycobacterium tuberculosis complex isolated from pulmonary tuberculosis patients in central Ethiopia. BMC Infect Dis. 2017;17(1):184.

37. Comas I, Hailu E, Kiros T, Bekele S, Mekonnen W, Gumi B, et al. Population Genomics of Mycobacterium tuberculosis in Ethiopia Contradicts the Virgin Soil Hypothesis for Human Tuberculosis in Sub-Saharan Africa. Curr Biol. 2015;25(24):3260-6.

38. Belay M, Ameni G, Bjune G, Couvin D, Rastogi N, Abebe F. Strain diversity of Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients in Afar pastoral region of Ethiopia. Biomed Res Int. 2014;2014:238532.

39. Beyene D, Bergval I, Hailu E, Ashenafi S, Yamuah L, Aseffa A, et al. Identification and genotyping of the etiological agent of tuberculous lymphadenitis in Ethiopia. J Infect Dev Ctries. 2009;3(6):412-9.

40. Tilahun M, Ameni G, Desta K, Zewude A, Yamuah L, Abebe M, et al. Molecular epidemiology and drug sensitivity pattern of Mycobacterium tuberculosis strains isolated from pulmonary tuberculosis patients in and around Ambo Town, Central Ethiopia. PLoS One. 2018;13(2):e0193083.

41. Tadesse M, Aragaw D, Dimah B, Efa F, Abdella K, Kebede W, et al. Drug resistance-conferring mutations in Mycobacterium tuberculosis from pulmonary tuberculosis patients in Southwest Ethiopia. Int J Mycobacteriol. 2016;5(2):185-91.

42. Tadesse M, Abebe G, Bekele A, Bezabih M, de Rijk P, Meehan CJ, et al. The predominance of Ethiopian specific Mycobacterium tuberculosis families and minimal contribution of Mycobacterium bovis in tuberculous lymphadenitis patients in Southwest Ethiopia. Infection, Genetics and Evolution. 2017;55:251-9.

43. Korma W, Mihret A, Hussien J, Anthony R, Lakew M, Aseffa A. Clinical, molecular and drug sensitivity pattern of mycobacterial isolates from extra-pulmonary tuberculosis cases in Addis Ababa, Ethiopia. BMC Infect Dis. 2015;15:456.

44. Zewdie O, Mihret A, Ameni G, Worku A, Gemechu T, Abebe T. Molecular typing of mycobacteria isolated from tuberculous lymphadenitis cases in Addis Ababa, Ethiopia. Int J Tuberc Lung Dis. 2016;20(11):1529-34.

45. Tessema B, Beer J, Merker M, Emmrich F, Sack U, Rodloff AC, et al. Molecular epidemiology and transmission dynamics of Mycobacterium tuberculosis in Northwest Ethiopia: new phylogenetic lineages found in Northwest Ethiopia. BMC Infect Dis. 2013;13:131.

46. Yimer SA, Hailu E, Derese Y, Bjune GA, Holm-Hansen C. Spoligotyping of Mycobacterium tuberculosis isolates among pulmonary tuberculosis patients in Amhara Region, Ethiopia. Apmis. 2013;121(9):878-85.

47. Yimer SA, Namouchi A, Zegeye ED, Holm-Hansen C, Norheim G, Abebe M, et al. Deciphering the recent phylogenetic expansion of the originally deeply rooted Mycobacterium tuberculosis lineage 7. BMC Evol Biol. 2016;16(1):146.

48. Yimer SA, Norheim G, Namouchi A, Zegeye ED, Kinander W, Tonjum T, et al. Mycobacterium tuberculosis lineage 7 strains are associated with prolonged patient delay in seeking treatment for pulmonary tuberculosis in Amhara Region, Ethiopia. J Clin Microbiol. 2015;53(4):1301-9.

49. Zewdie O, Mihret A, Abebe T, Kebede A, Desta K, Worku A, et al. Genotyping and molecular detection of multidrug-resistant Mycobacterium tuberculosis among tuberculosis lymphadenitis cases in Addis Ababa, Ethiopia. New Microbes and New Infections. 2018;21:36-41.

50. Biadglegne F, Merker M, Sack U, Rodloff AC, Niemann S. Tuberculous Lymphadenitis in Ethiopia Predominantly Caused by Strains Belonging to the Delhi/CAS Lineage and Newly Identified Ethiopian Clades of the Mycobacterium tuberculosis Complex. PLoS One. 2015;10(9):e0137865.

51. Biadglegne F, Mulu A, Rodloff AC, Sack U. Diagnostic performance of the Xpert MTB/RIF assay for tuberculous lymphadenitis on fine needle aspirates from Ethiopia. Tuberculosis (Edinb). 2014;94(5):502-5.

52. Garedew L, Mihret A, Ameni G. Molecular typing of mycobacteria isolated from extrapulmonary tuberculosis patients at Debre Birhan Referral Hospital, central Ethiopia. Scand J Infect Dis. 2013;45(7):512-8.

53. Garedew L, Mihret A, Mamo G, Abebe T, Firdessa R, Bekele Y, et al. Strain diversity of mycobacteria isolated from pulmonary tuberculosis patients at Debre Birhan Hospital, Ethiopia. Int J Tuberc Lung Dis. 2013;17(8):1076-81.

54. Gebrezgabiher G, Romha G, Ameni G. Spoligotyping of Mycobacterium tuberculosis isolates from tuberculosis diagnosed patients at Dilla University Referral Hospital and other private clinics, Southern Ethiopia. Asian Pacific Journal of Tropical Disease. 2015;5(4):329-33.

55. Getahun M, Ameni G, Kebede A, Yaregal Z, Hailu E, Medihn G, et al. Molecular typing and drug sensitivity testing of Mycobacterium tuberculosis isolated by a community-based survey in Ethiopia. BMC public health. 2015;15(1):751.

56. Diriba B, Berkessa T, Mamo G, Tedla Y, Ameni G. Spoligotyping of multidrug-resistant Mycobacterium tuberculosis isolates in Ethiopia. Int J Tuberc Lung Dis. 2013;17(2):246-50.

57. Debebe T, Admassu A, Mamo G, Ameni G. Molecular characterization of Mycobacterium tuberculosis isolated from pulmonary tuberculosis patients in Felege Hiwot Referral Hospital, northwest Ethiopia. J Microbiol Immunol Infect. 2014;47(4):333-8.

58. Deribew A, Abebe G, Apers L, Abdissa A, Deribe F, Woldemichael K, et al. Prevalence of pulmonary TB and spoligotype pattern of Mycobacterium tuberculosis among TB suspects in a rural community in Southwest Ethiopia. BMC Infect Dis. 2012;12:54.

59. Firdessa R, Berg S, Hailu E, Schelling E, Gumi B, Erenso G, et al. Mycobacterial lineages causing pulmonary and extrapulmonary tuberculosis, Ethiopia. Emerg Infect Dis. 2013;19(3):460-3.

60. Nebenzahl-Guimaraes H, Yimer SA, Holm-Hansen C, de Beer J, Brosch R, van Soolingen D. Genomic characterization of Mycobacterium tuberculosis lineage 7 and a proposed name:‘Aethiops vetus’. Microbial genomics. 2016;2(6).

61. Bekele S, Derese Y, Hailu E, Mihret A, Dagne K, Yamuah L, et al. Line-probe assay and molecular typing reveal a potential drug resistant clone of Mycobacterium tuberculosis in Ethiopia. Tropical diseases, travel medicine and vaccines. 2018;4:15.

62. Alame-Emane AK, Pierre-Audigier C, Aboumegone-Biyogo OC, Nzoghe-Mveang A, Cadet-Daniel V, Sola C, et al. Use of GeneXpert Remnants for Drug Resistance Profiling and Molecular Epidemiology of Tuberculosis in Libreville, Gabon. J Clin Microbiol. 2017;55(7):2105-15.

63. Homolka S, Meyer CG, Hillemann D, Owusu-Dabo E, Adjei O, Horstmann RD, et al. Unequal distribution of resistance-conferring mutations among Mycobacterium tuberculosis and Mycobacterium africanum strains from Ghana. Int J Med Microbiol. 2010;300(7):489-95.

64. Addo KK, Addo SO, Mensah GI, Mosi L, Bonsu FA. Genotyping and drug susceptibility testing of mycobacterial isolates from population-based tuberculosis prevalence survey in Ghana. BMC Infect Dis. 2017;17(1):743.

65. Yeboah-Manu D, Asare P, Asante-Poku A, Otchere ID, Osei-Wusu S, Danso E, et al. Spatio-Temporal Distribution of Mycobacterium tuberculosis Complex Strains in Ghana. PLoS One. 2016;11(8):e0161892.

66. Yeboah-Manu D, Asante-Poku A, Bodmer T, Stucki D, Koram K, Bonsu F, et al. Genotypic diversity and drug susceptibility patterns among M. tuberculosis complex isolates from South-Western Ghana. PLoS One. 2011;6(7):e21906.

67. Otchere ID, Asante-Poku A, Osei-Wusu S, Baddoo A, Sarpong E, Ganiyu AH, et al. Detection and characterization of drug-resistant conferring genes in Mycobacterium tuberculosis complex strains: A prospective study in two distant regions of Ghana. Tuberculosis (Edinb). 2016;99:147-54.

68. Asante-Poku A, Otchere ID, Danso E, Mensah DD, Bonsu F, Gagneux S, et al. Evaluation of GenoType MTBDRplus for the rapid detection of drug-resistant tuberculosis in Ghana. Int J Tuberc Lung Dis. 2015;19(8):954-9.

69. Asare P, Asante-Poku A, Prah DA, Borrell S, Osei-Wusu S, Otchere ID, et al. Reduced transmission of Mycobacterium africanum compared to Mycobacterium tuberculosis in urban West Africa. Int J Infect Dis. 2018;73:30-42.

70. Ejo M, Gehre F, Barry MD, Sow O, Bah NM, Camara M, et al. First insights into circulating Mycobacterium tuberculosis complex lineages and drug resistance in Guinea. Infect Genet Evol. 2015;33:314-9.

71. Rabna P, Ramos J, Ponce G, Sanca L, Mane M, Armada A, et al. Direct Detection by the Xpert MTB/RIF Assay and Characterization of Multi and Poly Drug-Resistant Tuberculosis in Guinea-Bissau, West Africa. PLoS One. 2015;10(5):e0127536.

72. Groenheit R, Ghebremichael S, Svensson J, Rabna P, Colombatti R, Riccardi F, et al. The Guinea-Bissau family of Mycobacterium tuberculosis complex revisited. PLoS One. 2011;6(4):e18601.

73. Rasoahanitralisoa R, Rakotosamimanana N, Stucki D, Sola C, Gagneux S, Rasolofo Razanamparany V. Evaluation of spoligotyping, SNPs and customised MIRU-VNTR combination for genotyping Mycobacterium tuberculosis clinical isolates in Madagascar. PLoS One. 2017;12(10):e0186088.

74. Chikaonda T, Ketseoglou I, Nguluwe N, Krysiak R, Thengolose I, Nyakwawa F, et al. Molecular characterisation of rifampicin-resistant Mycobacterium tuberculosis strains from Malawi. Afr J Lab Med. 2017;6(2):463.

75. Mallard K, McNerney R, Crampin AC, Houben R, Ndlovu R, Munthali L, et al. Molecular detection of mixed infections of Mycobacterium tuberculosis strains in sputum samples from patients in Karonga District, Malawi. J Clin Microbiol. 2010;48(12):4512-8.

76. Glynn JR, Crampin AC, Traore H, Chaguluka S, Mwafulirwa DT, Alghamdi S, et al. Determinants of cluster size in large, population-based molecular epidemiology study of tuberculosis, northern Malawi. Emerg Infect Dis. 2008;14(7):1060-6.

77. Traore B, Diarra B, Dembele BP, Somboro AM, Hammond AS, Siddiqui S, et al. Molecular strain typing of Mycobacterium tuberculosis complex in Bamako, Mali. Int J Tuberc Lung Dis. 2012;16(7):911-6.

78. Togo ACG, Kodio O, Diarra B, Sanogo M, Coulibaly G, Bane S, et al. The most frequent Mycobacterium tuberculosis complex families in mali (2006-2016) based on spoligotyping. Int J Mycobacteriol. 2017;6(4):379-86.

79. Chaoui I, Sabouni R, Kourout M, Jordaan AM, Lahlou O, Elouad R, et al. Analysis of isoniazid, streptomycin and ethambutol resistance in Mycobacterium tuberculosis isolates from Morocco. J Infect Dev Ctries. 2009;3(4):278-84.

80. Kourout M, Chaoui I, Sabouni R, Lahlou O, El Mzibri M, Jordaan A, et al. Molecular characterisation of rifampicin-resistant Mycobacterium tuberculosis strains from Morocco. Int J Tuberc Lung Dis. 2009;13(11):1440-2.

81. Ennassiri W, Jaouhari S, Cherki W, Charof R, Filali-Maltouf A, Lahlou O. Extensively drug-resistant tuberculosis (XDR-TB) in Morocco. Journal of global antimicrobial resistance. 2017;11:75-80.

82. Lahlou O, Millet J, Chaoui I, Sabouni R, Filali-Maltouf A, Akrim M, et al. The genotypic population structure of Mycobacterium tuberculosis complex from Moroccan patients reveals a predominance of Euro-American lineages. PLoS One. 2012;7(10):e47113.

83. Karimi H, En-Nanai L, Oudghiri A, Chaoui I, Laglaoui A, Bourkadi JE, et al. Performance of GenoType® MTBDRplus assay in the diagnosis of drug-resistant tuberculosis in Tangier, Morocco. Journal of global antimicrobial resistance. 2018;12:63-7.

84. Bouklata N, Supply P, Jaouhari S, Charof R, Seghrouchni F, Sadki K, et al. Molecular Typing of Mycobacterium Tuberculosis Complex by 24-Locus Based MIRU-VNTR Typing in Conjunction with Spoligotyping to Assess Genetic Diversity of Strains Circulating in Morocco. PLoS One. 2015;10(8):e0135695.

85. Chaoui I, Zozio T, Lahlou O, Sabouni R, Abid M, El Aouad R, et al. Contribution of spoligotyping and MIRU-VNTRs to characterize prevalent Mycobacterium tuberculosis genotypes infecting tuberculosis patients in Morocco. Infect Genet Evol. 2014;21:463-71.

86. Namburete EI, Tivane I, Lisboa M, Passeri M, Pocente R, Ferro JJ, et al. Drug-resistant tuberculosis in Central Mozambique: the role of a rapid genotypic susceptibility testing. BMC Infect Dis. 2016;16:423.

87. Bollela VR, Namburete EI, Feliciano CS, Macheque D, Harrison LH, Caminero JA. Detection of katG and inhA mutations to guide isoniazid and ethionamide use for drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2016;20(8):1099-104.

88. Viegas SO, Ghebremichael S, Massawo L, Alberto M, Fernandes FC, Monteiro E, et al. Mycobacterium tuberculosis causing tuberculous lymphadenitis in Maputo, Mozambique. BMC Microbiol. 2015;15:268.

89. Viegas SO, Machado A, Groenheit R, Ghebremichael S, Pennhag A, Gudo PS, et al. Molecular diversity of Mycobacterium tuberculosis isolates from patients with pulmonary tuberculosis in Mozambique. BMC Microbiol. 2010;10:195.

90. Saifodine A, Fyfe J, Sievers A, Coelho E, Azam K, Black J. Genetic diversity of Mycobacterium tuberculosis isolates obtained from patients with pulmonary tuberculosis in Beira city, Mozambique. Int J Mycobacteriol. 2014;3(2):94-100.

91. Feliciano CS, Namburete EI, Rodrigues Placa J, Peronni K, Dippenaar A, Warren RM, et al. Accuracy of whole genome sequencing versus phenotypic (MGIT) and commercial molecular tests for detection of drug-resistant Mycobacterium tuberculosis isolated from patients in Brazil and Mozambique. Tuberculosis (Edinb). 2018;110:59-67.

92. Cadmus S, Hill V, van Soolingen D, Rastogi N. Spoligotype profile of Mycobacterium tuberculosis complex strains from HIV-positive and -negative patients in Nigeria: a comparative analysis. J Clin Microbiol. 2011;49(1):220-6.

93. Thumamo BP, Asuquo AE, Abia-Bassey LN, Lawson L, Hill V, Zozio T, et al. Molecular epidemiology and genetic diversity of Mycobacterium tuberculosis complex in the Cross River State, Nigeria. Infect Genet Evol. 2012;12(4):671-7.

94. Ani A, Bruvik T, Okoh Y, Agaba P, Agbaji O, Idoko J, et al. Genetic diversity of Mycobacterium tuberculosis Complex in Jos, Nigeria. BMC Infect Dis. 2010;10:189.

95. Senghore M, Otu J, Witney A, Gehre F, Doughty EL, Kay GL, et al. Whole-genome sequencing illuminates the evolution and spread of multidrug-resistant tuberculosis in Southwest Nigeria. PLoS One. 2017;12(9):e0184510.

96. Uzoewulu GN, Lawson L, Nnanna IS, Rastogi N, Goyal M. Genetic diversity of Mycobacterium tuberculosis complex strains isolated from patients with pulmonary tuberculosis in Anambra State, Nigeria. Int J Mycobacteriol. 2016;5(1):74-9.

97. Lawson L, Zhang J, Gomgnimbou MK, Abdurrahman ST, Le Moullec S, Mohamed F, et al. A molecular epidemiological and genetic diversity study of tuberculosis in Ibadan, Nnewi and Abuja, Nigeria. PLoS One. 2012;7(6):e38409.

98. Molina-Moya B, Gomgnimbou MK, Spinasse L, Obasanya J, Oladimeji O, Dacombe R, et al. Mycobacterium tuberculosis complex genotypes circulating in Nigeria based on spoligotyping obtained from Ziehl-Neelsen stained slides extracted DNA. PLoS Negl Trop Dis. 2018;12(2):e0006242.

99. Dinic L, Akande P, Idigbe EO, Ani A, Onwujekwe D, Agbaji O, et al. Genetic determinants of drug-resistant tuberculosis among HIV-infected patients in Nigeria. J Clin Microbiol. 2012;50(9):2905-9.

100. Umubyeyi AN, Rigouts L, Shamputa IC, Fissette K, Elkrim Y, De Rijk P, et al. Limited fluoroquinolone resistance among Mycobacterium tuberculosis isolates from Rwanda: results of a national survey. Journal of antimicrobial chemotherapy. 2007;59(5):1031-3.

101. Gafirita J, Umubyeyi AN, Asiimwe BB. A first insight into the genotypic diversity of Mycobacterium tuberculosis from Rwanda. BMC Clin Pathol. 2012;12:20.

102. Feuerriegel S, Oberhauser B, George AG, Dafae F, Richter E, Rusch-Gerdes S, et al. Sequence analysis for detection of first-line drug resistance in Mycobacterium tuberculosis strains from a high-incidence setting. BMC Microbiol. 2012;12:90.

103. Homolka S, Post E, Oberhauser B, George AG, Westman L, Dafae F, et al. High genetic diversity among Mycobacterium tuberculosis complex strains from Sierra Leone. BMC Microbiol. 2008;8:103.

104. Allana S, Shashkina E, Mathema B, Bablishvili N, Tukvadze N, Shah NS, et al. pncA gene mutations associated with pyrazinamide resistance in drug-resistant tuberculosis, South Africa and Georgia. Emerging infectious diseases. 2017;23(3):491.

105. Ioerger TR, Koo S, No EG, Chen X, Larsen MH, Jacobs WR, Jr., et al. Genome analysis of multi- and extensively-drug-resistant tuberculosis from KwaZulu-Natal, South Africa. PLoS One. 2009;4(11):e7778.

106. Mathema B, Lewis JJ, Connors J, Chihota VN, Shashkina E, van der Meulen M, et al. Molecular epidemiology of Mycobacterium tuberculosis among South African gold miners. Ann Am Thorac Soc. 2015;12(1):12-20.

107. Stavrum R, Mphahlele M, Ovreas K, Muthivhi T, Fourie PB, Weyer K, et al. High diversity of Mycobacterium tuberculosis genotypes in South Africa and preponderance of mixed infections among ST53 isolates. J Clin Microbiol. 2009;47(6):1848-56.

108. Said HM, Kock MM, Ismail NA, Mphahlele M, Baba K, Omar SV, et al. Molecular characterization and second-line antituberculosis drug resistance patterns of multidrug-resistant Mycobacterium tuberculosis isolates from the northern region of South Africa. J Clin Microbiol. 2012;50(9):2857-62.

109. Mlambo CK, Warren RM, Poswa X, Victor TC, Duse AG, Marais E. Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa. Int J Tuberc Lung Dis. 2008;12(1):99-104.

110. Maningi NE, Daum LT, Rodriguez JD, Mphahlele M, Peters RP, Fischer GW, et al. Improved Detection by Next-Generation Sequencing of Pyrazinamide Resistance in Mycobacterium tuberculosis Isolates. J Clin Microbiol. 2015;53(12):3779-83.

111. Maningi NE, Daum LT, Rodriguez JD, Said HM, Peters RPH, Sekyere JO, et al. Multi- and Extensively Drug Resistant Mycobacterium tuberculosis in South Africa: a Molecular Analysis of Historical Isolates. J Clin Microbiol. 2018;56(5).

112. Maningi NE, Malinga LA, Antiabong JF, Lekalakala RM, Mbelle NM. Comparison of line probe assay to BACTEC MGIT 960 system for susceptibility testing of first and second-line anti-tuberculosis drugs in a referral laboratory in South Africa. BMC Infect Dis. 2017;17(1):795.

113. Marais BJ, Hesseling AC, Schaaf HS, Gie RP, van Helden PD, Warren RM. Mycobacterium tuberculosis transmission is not related to household genotype in a setting of high endemicity. J Clin Microbiol. 2009;47(5):1338-43.

114. Marais BJ, Mlambo CK, Rastogi N, Zozio T, Duse AG, Victor TC, et al. Epidemic spread of multidrug-resistant tuberculosis in Johannesburg, South Africa. J Clin Microbiol. 2013;51(6):1818-25.

115. Maguga-Phasha NTC, Munyai NS, Mashinya F, Makgatho ME, Mbajiorgu EF. Genetic diversity and distribution of Mycobacterium tuberculosis genotypes in Limpopo, South Africa. BMC Infect Dis. 2017;17(1):764.

116. Malinga L, Brand J, Olorunju S, Stoltz A, van der Walt M. Molecular analysis of genetic mutations among cross-resistant second-line injectable drugs reveals a new resistant mutation in Mycobacterium tuberculosis. Diagn Microbiol Infect Dis. 2016;85(4):433-7.

117. Kamudumuli PS, Beylis N, Blann L, Duse A. Molecular typing of drug-susceptible and -resistant Mycobacterium tuberculosis in Johannesburg, South Africa. Int J Tuberc Lung Dis. 2015;19(7):834-40.

118. Cohen T, Wilson D, Wallengren K, Samuel EY, Murray M. Mixed-strain Mycobacterium tuberculosis infections among patients dying in a hospital in KwaZulu-Natal, South Africa. J Clin Microbiol. 2011;49(1):385-8.

119. Green E, Obi L, Nchabeleng M, De Villiers B, Sein P, Letsoalo T, et al. Molecular characterisation of resistant Mycobacterium tuberculosis isolates from Dr George Mukhari Hospital, Pretoria, South Africa. Southern African Journal of Epidemiology and Infection. 2008;23(3):11-4.

120. Gandhi NR, Brust JC, Moodley P, Weissman D, Heo M, Ning Y, et al. Minimal diversity of drug-resistant Mycobacterium tuberculosis strains, South Africa. Emerg Infect Dis. 2014;20(3):426-33.

121. Gardee Y, Dreyer AW, Koornhof HJ, Omar SV, da Silva P, Bhyat Z, et al. Evaluation of the GenoType MTBDRsl Version 2.0 Assay for Second-Line Drug Resistance Detection of Mycobacterium tuberculosis Isolates in South Africa. J Clin Microbiol. 2017;55(3):791-800.

122. Dorman SE, Chihota VN, Lewis JJ, van der Meulen M, Mathema B, Beylis N, et al. Genotype MTBDRplus for direct detection of Mycobacterium tuberculosis and drug resistance in strains from gold miners in South Africa. J Clin Microbiol. 2012;50(4):1189-94.

123. Dramowski A, Morsheimer MM, Jordaan AM, Victor TC, Donald PR, Schaaf HS. Rifampicin-monoresistant Mycobacterium tuberculosis disease among children in Cape Town, South Africa. Int J Tuberc Lung Dis. 2012;16(1):76-81.

124. Daum LT, Rodriguez JD, Worthy SA, Ismail NA, Omar SV, Dreyer AW, et al. Next-generation ion torrent sequencing of drug resistance mutations in Mycobacterium tuberculosis strains. J Clin Microbiol. 2012;50(12):3831-7.

125. Farhat MR, Jacobson KR, Franke MF, Kaur D, Sloutsky A, Mitnick CD, et al. Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis. J Clin Microbiol. 2016;54(3):727-33.

126. Dookie N, Sturm AW, Moodley P. Mechanisms of first-line antimicrobial resistance in multi-drug and extensively drug resistant strains of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. BMC Infect Dis. 2016;16(1):609.

127. Rukasha I, Said HM, Omar SV, Koornhof H, Dreyer AW, Musekiwa A, et al. Correlation of rpoB Mutations with Minimal Inhibitory Concentration of Rifampin and Rifabutin in Mycobacterium tuberculosis in an HIV/AIDS Endemic Setting, South Africa. Front Microbiol. 2016;7:1947.

128. Niehaus AJ, Mlisana K, Gandhi NR, Mathema B, Brust JC. High Prevalence of inhA Promoter Mutations among Patients with Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa. PLoS One. 2015;10(9):e0135003.

129. Pietersen E, Peter J, Streicher E, Sirgel F, Rockwood N, Mastrapa B, et al. High frequency of resistance, lack of clinical benefit, and poor outcomes in capreomycin treated South African patients with extensively drug-resistant tuberculosis. PloS one. 2015;10(4):e0123655.

130. O'Donnell MR, Pillay M, Pillay M, Werner L, Master I, Wolf A, et al. Primary Capreomycin Resistance Is Common and Associated With Early Mortality in Patients With Extensively Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr. 2015;69(5):536-43.

131. Dookie N, Sturm AW, Moodley P. Moxifloxacin resistance in the F15/LAM4/KZN extensively drug-resistant strain of Mycobacterium tuberculosis. Infect Drug Resist. 2014;7:223-8.

132. Bhembe NL, Nwodo UU, Govender S, Hayes C, Ndip RN, Okoh AI, et al. Molecular detection and characterization of resistant genes in Mycobacterium tuberculosis complex from DNA isolated from tuberculosis patients in the Eastern Cape province South Africa. BMC Infect Dis. 2014;14:479.

133. Muller B, Chihota VN, Pillay M, Klopper M, Streicher EM, Coetzee G, et al. Programmatically selected multidrug-resistant strains drive the emergence of extensively drug-resistant tuberculosis in South Africa. PLoS One. 2013;8(8):e70919.

134. de Vos M, Muller B, Borrell S, Black PA, van Helden PD, Warren RM, et al. Putative compensatory mutations in the rpoC gene of rifampin-resistant Mycobacterium tuberculosis are associated with ongoing transmission. Antimicrob Agents Chemother. 2013;57(2):827-32.

135. Klopper M, Warren RM, Hayes C, Gey van Pittius NC, Streicher EM, Muller B, et al. Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa. Emerg Infect Dis. 2013;19(3):449-55.

136. Sirgel FA, Tait M, Warren RM, Streicher EM, Bottger EC, van Helden PD, et al. Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis. Microb Drug Resist. 2012;18(2):193-7.

137. Silaigwana B, Green E, Ndip RN. Molecular detection and drug resistance of Mycobacterium tuberculosis complex from cattle at a dairy farm in the Nkonkobe region of South Africa: a pilot study. Int J Environ Res Public Health. 2012;9(6):2045-56.

138. Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Bottger EC. embB306 mutations as molecular indicators to predict ethambutol susceptibility in Mycobacterium tuberculosis. Chemotherapy. 2012;58(5):358-63.

139. Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Bottger EC. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother. 2012;67(5):1088-93.

140. Streicher EM, Bergval I, Dheda K, Bottger EC, Gey van Pittius NC, Bosman M, et al. Mycobacterium tuberculosis population structure determines the outcome of genetics-based second-line drug resistance testing. Antimicrob Agents Chemother. 2012;56(5):2420-7.

141. Evans J, Segal H. Novel multiplex allele-specific PCR assays for the detection of resistance to second-line drugs in Mycobacterium tuberculosis. J Antimicrob Chemother. 2010;65(5):897-900.

142. Mphahlele M, Syre H, Valvatne H, Stavrum R, Mannsaker T, Muthivhi T, et al. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J Clin Microbiol. 2008;46(10):3459-64.

143. Chihota VN, Muller B, Mlambo CK, Pillay M, Tait M, Streicher EM, et al. Population structure of multi- and extensively drug-resistant Mycobacterium tuberculosis strains in South Africa. J Clin Microbiol. 2012;50(3):995-1002.

144. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med. 2008;177(7):787-92.

145. Bryant JM, Harris SR, Parkhill J, Dawson R, Diacon AH, van Helden P, et al. Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study. The Lancet Respiratory medicine. 2013;1(10):786-92.

146. Cornejo-Granados F, Zatarain-Barrón ZL, Cantu-Robles VA, Mendoza-Vargas A, Molina-Romero C, Sánchez F, et al. Secretome prediction of two M. tuberculosis clinical isolates reveals their high antigenic density and potential drug targets. Front Microbiol. 2017;8:128.

147. Ioerger TR, Feng Y, Chen X, Dobos KM, Victor TC, Streicher EM, et al. The non-clonality of drug resistance in Beijing-genotype isolates of Mycobacterium tuberculosis from the Western Cape of South Africa. BMC Genomics. 2010;11:670.

148. Malinga LA, Abeel T, Desjardins CA, Dlamini TC, Cassell G, Chapman SB, et al. Draft genome sequences of two extensively drug-resistant strains of Mycobacterium tuberculosis belonging to the Euro-American S lineage. Genome announcements. 2016;4(2):e01771-15.

149. Makhado NA, Matabane E, Faccin M, Pincon C, Jouet A, Boutachkourt F, et al. Outbreak of multidrug-resistant tuberculosis in South Africa undetected by WHO-endorsed commercial tests: an observational study. Lancet Infect Dis. 2018;18(12):1350-9.

150. Andre E, Goeminne L, Colmant A, Beckert P, Niemann S, Delmee M. Novel rapid PCR for the detection of Ile491Phe rpoB mutation of Mycobacterium tuberculosis, a rifampicin-resistance-conferring mutation undetected by commercial assays. Clin Microbiol Infect. 2017;23(4):267.e5-.e7.

151. Sanchez-Padilla E, Merker M, Beckert P, Jochims F, Dlamini T, Kahn P, et al. Detection of drug-resistant tuberculosis by Xpert MTB/RIF in Swaziland. N Engl J Med. 2015;372(12):1181-2.

152. Sabeel S, Salih MA, Ali M, EL-Zaki S-E, Abuzeid N, Elgadi ZAM, et al. Phenotypic and Genotypic Analysis of Multidrug-Resistant Mycobacterium tuberculosis Isolates from Sudanese Patients. Tuberculosis research and treatment. 2017;2017.

153. Khalid FA, Hamid ZA, Mukhtar MM. Tuberculosis drug resistance isolates from pulmonary tuberculosis patients, Kassala State, Sudan. Int J Mycobacteriol. 2015;4(1):44-7.

154. Elbir H, Ibrahim NY. Frequency of mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis clinical isolates from Sudan. J Infect Dev Ctries. 2014;8(6):796-8.

155. Sharaf Eldin GS, Fadl-Elmula I, Ali MS, Ali AB, Salih AL, Mallard K, et al. Tuberculosis in Sudan: a study of Mycobacterium tuberculosis strain genotype and susceptibility to anti-tuberculosis drugs. BMC Infect Dis. 2011;11:219.

156. Abdul-Aziz AA, Elhassan MM, Abdulsalam SA, Mohammed EO, Hamid ME. Multi-drug resistance tuberculosis (MDR-TB) in Kassala State, Eastern Sudan. Trop Doct. 2013;43(2):66-70.

157. Mpagama SG, Houpt ER, Stroup S, Kumburu H, Gratz J, Kibiki GS, et al. Application of quantitative second-line drug susceptibility testing at a multidrug-resistant tuberculosis hospital in Tanzania. BMC infectious diseases. 2013;13(1):432.

158. Mbugi EV, Katale BZ, Siame KK, Keyyu JD, Kendall SL, Dockrell HM, et al. Genetic diversity of Mycobacterium tuberculosis isolated from tuberculosis patients in the Serengeti ecosystem in Tanzania. Tuberculosis (Edinb). 2015;95(2):170-8.

159. Stavrum R, PrayGod G, Range N, Faurholt-Jepsen D, Jeremiah K, Faurholt-Jepsen M, et al. Increased level of acute phase reactants in patients infected with modern Mycobacterium tuberculosis genotypes in Mwanza, Tanzania. BMC Infect Dis. 2014;14:309.

160. Olaru ID, Rachow A, Lange C, Ntinginya NE, Reither K, Hoelscher M, et al. Ascertaining in vivo virulence of Mycobacterium tuberculosis lineages in patients in Mbeya, Tanzania. Int J Tuberc Lung Dis. 2015;19(1):70-3.

161. Mbugi EV, Katale BZ, Streicher EM, Keyyu JD, Kendall SL, Dockrell HM, et al. Mapping of Mycobacterium tuberculosis Complex Genetic Diversity Profiles in Tanzania and Other African Countries. PLoS One. 2016;11(5):e0154571.

162. Mfinanga SG, Warren RM, Kazwala R, Kahwa A, Kazimoto T, Kimaro G, et al. Genetic profile of Mycobacterium tuberculosis and treatment outcomes in human pulmonary tuberculosis in Tanzania. Tanzan J Health Res. 2014;16(2):58-69.

163. Hoza AS, Mfinanga SG, Moser I, Konig B. Molecular characterization of Mycobacterium tuberculosis isolates from Tanga, Tanzania: First insight of MIRU-VNTR and microarray-based spoligotyping in a high burden country. Tuberculosis (Edinb). 2016;98:116-24.

164. Kidenya BR, Mshana SE, Fitzgerald DW, Ocheretina O. Genotypic drug resistance using whole-genome sequencing of Mycobacterium tuberculosis clinical isolates from North-western Tanzania. Tuberculosis (Edinb). 2018;109:97-101.

165. Kibiki GS, Mulder B, Dolmans WM, de Beer JL, Boeree M, Sam N, et al. M. tuberculosis genotypic diversity and drug susceptibility pattern in HIV-infected and non-HIV-infected patients in northern Tanzania. BMC Microbiol. 2007;7:51.

166. Soudani A, Hadjfredj S, Zribi M, Messaoud T, Masmoudi A, Majed B, et al. First report of molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates from a Tunisian hospital. Clin Microbiol Infect. 2010;16(9):1454-7.

167. Soudani A, Hadjfredj S, Zribi M, Masmoudi A, Messaoud T, Tiouri H, et al. Characterization of Tunisian Mycobacterium tuberculosis rifampin-resistant clinical isolates. J Clin Microbiol. 2007;45(9):3095-7.

168. Ben Kahla I, Marzouk M, Henry M, Bedotto M, Cohen-Bacrie S, Ben Selma W, et al. Molecular characterisation of isoniazid- and rifampicin-resistant Mycobacterium tuberculosis in Central Tunisia. Int J Tuberc Lung Dis. 2011;15(12):1685-8.

169. Namouchi A, Karboul A, Mhenni B, Khabouchi N, Haltiti R, Ben Hassine R, et al. Genetic profiling of Mycobacterium tuberculosis in Tunisia: predominance and evidence for the establishment of a few genotypes. J Med Microbiol. 2008;57(Pt 7):864-72.

170. Mboowa G, Namaganda C, Ssengooba W. Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert(R) MTB/RIF in Kampala, Uganda: a retrospective study. BMC Infect Dis. 2014;14:481.

171. Bazira J, Asiimwe BB, Joloba ML, Bwanga F, Matee MI. Mycobacterium tuberculosis spoligotypes and drug susceptibility pattern of isolates from tuberculosis patients in South-Western Uganda. BMC Infect Dis. 2011;11:81.

172. Asiimwe BB, Ghebremichael S, Kallenius G, Koivula T, Joloba ML. Mycobacterium tuberculosis spoligotypes and drug susceptibility pattern of isolates from tuberculosis patients in peri-urban Kampala, Uganda. BMC Infect Dis. 2008;8:101.

173. Ssengooba W, Meehan CJ, Lukoye D, Kasule GW, Musisi K, Joloba ML, et al. Whole genome sequencing to complement tuberculosis drug resistance surveys in Uganda. Infect Genet Evol. 2016;40:8-16.

174. Wampande EM, Mupere E, Jaganath D, Nsereko M, Mayanja HK, Eisenach K, et al. Distribution and transmission of Mycobacterium tuberculosis complex lineages among children in peri-urban Kampala, Uganda. BMC Pediatr. 2015;15:140.

175. Wamala D, Okee M, Kigozi E, Couvin D, Rastogi N, Joloba M, et al. Predominance of Uganda genotype of Mycobacterium tuberculosis isolated from Ugandan patients with tuberculous lymphadenitis. BMC Res Notes. 2015;8:398.

176. Wampande EM, Mupere E, Debanne SM, Asiimwe BB, Nsereko M, Mayanja H, et al. Long-term dominance of Mycobacterium tuberculosis Uganda family in peri-urban Kampala-Uganda is not associated with cavitary disease. BMC Infect Dis. 2013;13:484.

177. Muwonge A, Malama S, Johansen TB, Kankya C, Biffa D, Ssengooba W, et al. Molecular epidemiology, drug susceptibility and economic aspects of tuberculosis in Mubende district, Uganda. PLoS One. 2013;8(5):e64745.

178. Lukoye D, Katabazi FA, Musisi K, Kateete DP, Asiimwe BB, Okee M, et al. The T2 Mycobacterium tuberculosis genotype, predominant in Kampala, Uganda, shows negative correlation with antituberculosis drug resistance. Antimicrob Agents Chemother. 2014;58(7):3853-9.

179. Asiimwe BB, Koivula T, Kallenius G, Huard RC, Ghebremichael S, Asiimwe J, et al. Mycobacterium tuberculosis Uganda genotype is the predominant cause of TB in Kampala, Uganda. Int J Tuberc Lung Dis. 2008;12(4):386-91.

180. Clark TG, Mallard K, Coll F, Preston M, Assefa S, Harris D, et al. Elucidating emergence and transmission of multidrug-resistant tuberculosis in treatment experienced patients by whole genome sequencing. PLoS One. 2013;8(12):e83012.

181. Wanzala SI, Nakavuma J, Travis DA, Kia P, Ogwang S, Sreevatsan S. Draft genome sequences of Mycobacterium bovis BZ 31150 and Mycobacterium bovis B2 7505, pathogenic bacteria isolated from archived captive animal bronchial washes and human sputum samples in Uganda. Genome announcements. 2015;3(5):e01102-15.

182. Kigozi E, Kasule GW, Musisi K, Lukoye D, Kyobe S, Katabazi FA, et al. Prevalence and patterns of rifampicin and isoniazid resistance conferring mutations in Mycobacterium tuberculosis isolates from Uganda. PLoS One. 2018;13(5):e0198091.

183. Bwalya P, Yamaguchi T, Mulundu G, Nakajima C, Mbulo G, Solo ES, et al. Genotypic characterization of pyrazinamide resistance in Mycobacterium tuberculosis isolated from Lusaka, Zambia. Tuberculosis (Edinb). 2018;109:117-22.

184. Mulenga C, Shamputa IC, Mwakazanga D, Kapata N, Portaels F, Rigouts L. Diversity of Mycobacterium tuberculosis genotypes circulating in Ndola, Zambia. BMC Infect Dis. 2010;10:177.

185. Chihota V, Apers L, Mungofa S, Kasongo W, Nyoni IM, Tembwe R, et al. Predominance of a single genotype of Mycobacterium tuberculosis in regions of Southern Africa. Int J Tuberc Lung Dis. 2007;11(3):311-8.

186. Takawira FT, Mandishora RSD, Dhlamini Z, Munemo E, Stray-Pedersen B. Mutations in rpoB and katG genes of multidrug resistant mycobacterium tuberculosis undetectable using genotyping diagnostic methods. Pan Afr Med J. 2017;27:145.

1. Isoniazid [↑](#footnote-ref-1)
2. Rifampicin/Rifampin [↑](#footnote-ref-2)
3. Streptomycin [↑](#footnote-ref-3)
4. Ethambutol [↑](#footnote-ref-4)
5. Moxifloxacin [↑](#footnote-ref-5)
6. Ofloxacin [↑](#footnote-ref-6)
7. Amikacin [↑](#footnote-ref-7)
8. Pyrazinamide [↑](#footnote-ref-8)
9. Ethionamide [↑](#footnote-ref-9)
10. Kanamycin [↑](#footnote-ref-10)
11. Fluoroquinolone [↑](#footnote-ref-11)
12. Capreomycin [↑](#footnote-ref-12)
13. Rifabutin [↑](#footnote-ref-13)
14. Ciprofloxacin [↑](#footnote-ref-14)